var title_f20_20_20800="MAP osteosarcoma young adults and children";
var content_f20_20_20800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cisplatin, doxorubicin, and methotrexate for non-metastatic high-grade osteosarcoma in young adults and children",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"5\">",
"        Cycle length: 5 weeks (cycles 1 through 4), 4 weeks (cycle 5 and 6).",
"        <br/>",
"        Duration of therapy: 6 cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Week of treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin*",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV (total dose = 120 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per cycle)",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) and administer over four hours. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        <p>",
"         Preoperative: Weeks 1 and 6",
"        </p>",
"        Postoperative: Weeks 12 and 17",
"       </td>",
"       <td>",
"        Days 1 and 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin*",
"        </strong>",
"       </td>",
"       <td>",
"        37.5 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV (total dose = 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per cycle)",
"       </td>",
"       <td>",
"        <p>",
"         Dilute in 1000 mL NS",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and administer as a continuous IV infusion over 24 hours daily.",
"        </p>",
"        Alternative: dilute with NS to a final concentration of 2 mg/mL and administer as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5 percent dextrose in water (D5W). Final solution should be protected from light.",
"       </td>",
"       <td>",
"        <p>",
"         Preoperative: Weeks 1 and 6",
"        </p>",
"        Postoperative: Weeks 12, 17, 22, and 26",
"       </td>",
"       <td>",
"        Days 1 through 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Methotrexate*",
"        </strong>",
"       </td>",
"       <td>",
"        12 g/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute in 500 mL D5W and administer over four hours. Final solution should be protected from light.",
"       </td>",
"       <td>",
"        <p>",
"         Preoperative: Week 4, 5, 9, and 10",
"        </p>",
"        Postoperative: Week 15, 16, 20, 21, 24, 25, 28, and 29",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"       </td>",
"       <td>",
"        15 mg orally, IV, or IM every six hours (adjust dose according to serum methotrexate concentrations",
"        <sup>",
"         &yen;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        Begin 24 hours after start of methotrexate infusion and continue until serum methotrexate concentration is less than 0.1 micromol/L",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        <p>",
"         Preoperative: Week 4, 5, 9, and 10",
"        </p>",
"        Postoperative: Week 15, 16, 20, 21, 24, 25, 28, and 29",
"       </td>",
"       <td>",
"        Begin 24 hours after start of methotrexate infusion and continue until serum methotrexate concentration is less than 0.1 micromol/L",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Surgery",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Week 11",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - Cisplatin: Normal saline-based IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Alternative: pretreatment hydration with 1 to 2 L of normal saline-based fluid infused for 8 to 12 hours prior to each dose of cisplatin",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - Methotrexate: Adequate IV fluid (approximately 125 to 150 mL/hour) with electrolytes and bicarbonate must be given to maintain adequate urine output and alkalinization for methotrexate clearance. A urine pH &gt;7 must be achieved before starting the methotrexate infusion and maintained until the methotrexate serum level is &lt;0.1 micromol/L. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Cisplatin plus doxorubicin = HIGH. Methotrexate = LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen for cisplatin, doxorubicin, or methotrexate. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage with a large volume, concentrated extravasation; avoid extravasation. Doxorubicin is a vesicant; avoid extravasation. Administer infusions of doxorubicin through a central venous line. Refer to UpToDate topic on \"Chemotherapy extravasation injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        The AOST 0331/EURAMOS-1 protocol recommended secondary prophylaxis with G-CSF after doxorubicin/cisplatin cycles if prior doxorubicin/cisplatin cycles were complicated by fever and neutropenia with non-catheter-related sepsis or prolonged hospitalization (&gt;7 days). However, many centers give G-CSF with each cycle of doxorubicin/cisplatin. If given, begin growth factor support at least 24 hours after completion of chemotherapy; if given daily, continue until WBC &ge;5000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        after the nadir, and discontinue at least two days prior to next course of chemotherapy. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction and third-space fluid collections:",
"        </strong>",
"        A lower starting dose of cisplatin and methotrexate may be needed for patients with renal impairment, although the optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Many clinicians would decrease the initial dose of cisplatin for a creatinine clearance &lt;50 mL/min. A lower starting dose of doxorubicin and methotrexate may be needed for patients with liver impairment. In the AOST0331 protocol: for total bilirubin greater than or equal to 1.25 mg/dL and less than 2.1 mg/dL, doxorubicin doses were reduced by 25 percent; for total bilirubin greater than or equal to 2.1 mg/dL and less than 3.06 mg/dL, doxorubicin doses were reduced by 50 percent; for total bilirubin greater than or equal to 3.06 mg/dL and less than 5 mg/dL, doxorubicin doses were reduced by 75 percent; and for total bilirubin greater than or equal to 5 mg/dL ,doxorubicin was omitted",
"        <sup>",
"         [1]",
"        </sup>",
"        . For patients with third space fluid collections (eg, ascites, pleural effusion), await resolution or perform drainage before initiating methotrexate. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", and \"Therapeutic use and toxicity of high-dose methotrexate\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Doxorubicin is associated with dose-dependent cardiomyopathy; the incidence is related to cumulative dose. The risk of developing congestive heart failure increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . Cardiac toxicity may occur at lower cumulative doses whether or not cardiac risk factors are present. Assess baseline LVEF prior to initiating therapy. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Prevention of high dose methotrexate toxicity:",
"        </strong>",
"        Maintaining urine output, alkalinization of the urine, monitoring methotrexate concentrations, providing leucovorin rescue, identifying and avoiding drug-drug interactions (eg, use with penicillins, cephalosporins, nonsteroidal anti-inflammatory agents, proton-pump inhibitors, etc), and monitoring electrolytes and renal function are important in the prevention of methotrexate toxicity. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; CBC with differential prior to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Assess electrolytes and liver and renal function prior to treatment and daily during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Baseline audiometry, monitor for hearing loss prior to each dose of cisplatin; repeat audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Assess change in neurologic function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Assess patient for third-space fluid collection prior to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Monitor for diarrhea, stomatitis, and cutaneous toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Monitor for clinically significant nausea and vomiting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Monitor serum methotrexate concentration daily starting 24 hours after the start of the methotrexate infusion and continue until serum methotrexate level is &lt;0.1 micromol/L (microM). If toxic concentrations of methotrexate with reduced clearance occur in the setting of renal insufficiency, consider emergent use of glucarpidase. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Monitor daily fluid balance (intake and output), weight, CBC with differential, platelets, blood pressure, LFTs (AST, ALT, total bilirubin), and serum creatinine daily during and after methotrexate therapy until the methotrexate serum level is &lt;0.1 micromol/L (microM).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull; Monitor cumulative doxorubicin dose. Reassess LVEF periodically during doxorubicin therapy as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - For cycles of cisplatin plus doxorubicin, hold treatment until ANC &ge;750 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is &ge;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If ANC and platelets recovery is &le;7 days, no dose adjustment is required. If recovery is delayed &gt;7 days or if there is febrile neutropenia with prolonged hospitalization, decrease the cisplatin dose by 25 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - For high dose methotrexate, if the ANC &lt;250 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &lt;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , hold methotrexate until adequate hematologic recovery occurs",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Audiology:",
"        </strong>",
"        For any hearing loss with a threshold greater than 30 dB at less than or equal to 2 kHz, discontinue cisplatin",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Cardiotoxicity:",
"        </strong>",
"        For LVEF less than 50 percent or shortening fraction less than 28 percent, repeat MUGA or ECHO in one week. If the MUGA or ECHO is within normal limits, then proceed with chemotherapy. If LVEF does not normalize after one week, omit all further doxorubicin",
"        <sup>",
"         [1]",
"        </sup>",
"        . There are no prospective data on the use of the cardioprotective agent dexrazoxane in osteosarcoma therapy, particularly in children. Dexrazoxane may be used if a 10 percent decrease in LVEF or similar decrease within the normal range of shortening fraction (ECHO) occurs. Some clinicians add dexrazoxane once cumulative doxorubicin dose reaches 225 to 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . If cardioprotection is used, doxorubicin should be administered daily over 15 minutes immediately following dexrazoxane.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - For elevated LFTs that are not methotrexate induced, delay methotrexate treatment for one week and administer methotrexate if ALT is less than 10 times normal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - For elevated LFTs that are probably methotrexate induced (ie, up to three weeks after methotrexate), it is expected that patients receiving high dose methotrexate will develop hypertransaminasemia and occasionally hyperbilirubinemia. These elevations can last up to two weeks following the methotrexate infusion and should not be considered toxicity requiring dose reduction or discontinuation of the drug. However, for total bilirubin greater than 1.5 times normal for longer than three weeks, discontinue methotrexate",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Mucositis, severe abdominal pain, diarrhea, and typhlitis:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - For grade 4 mucositis or typhlitis or repeated grade 3 mucositis, hold cisplatin and doxorubicin until toxicity has resolved and then decrease subsequent doxorubicin total dose to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per cycle",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - For grade 3 or 4 mucositis or diarrhea after methotrexate, consider leucovorin rescue dose adjustment",
"        <sup>",
"         &yen;[1]",
"        </sup>",
"        . Also, maximize measures for methotrexate elimination. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - If grade 3 or 4 mucositis or diarrhea after methotrexate in week 4 (cycle 1) and it persists for greater than one week, omit week 5 methotrexate and proceed to week 6 of preoperative chemotherapy (or surgery)",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - Hold cisplatin if serum creatinine is greater than twice baseline or if GFR &lt;70 mL/min/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        . If renal function does not improve, omit cisplatin and administer doxorubicin alone. Cisplatin can be restarted in future courses if GFR improves to &ge;70 mL/min/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"5\">",
"        - Hold methotrexate treatment if GFR &lt;70 mL/min/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        until GFR is &ge;70 mL/min/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        . If renal function does not improve within one week, then omit methotrexate and proceed to the next possible cycle. If renal function subsequently improves, resume methotrexate",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        &bull;",
"        <strong>",
"         Peripheral neurotoxicity:",
"        </strong>",
"        Neuropathy is usually seen with cumulative doses of cisplatin greater than 400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. As per the original protocol, for grade 2 peripheral neurotoxicity, reduce cisplatin dose by 25 percent for all future courses; for &ge;grade 3 peripheral neurotoxicity, omit cisplatin for all future cycles",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent (except for cases of limb loss during surgery), doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician who is trained in the use of this specific type of chemotherapy regimen. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; IM: intramuscular; ECHO: echocardiogram; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; AST: aspartate aminotransferase; LVEF: ventricular ejection fraction; ANC: absolute neutrophil count; MUGA: multigated acquisition scan; LFTs: liver function tests; ALT: alanine aminotransferase; GFR: glomerular filtration rate.",
"     <br>",
"      * Chemotherapy doses should be calculated according to presurgery body surface area (using actual body weight) with no adjustment for postoperative limb loss",
"      <sup>",
"       [1]",
"      </sup>",
"      .",
"      <br>",
"       &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Some pediatric centers limit the methotrexate dose to 20 grams",
"        <sup>",
"         [3]",
"        </sup>",
"        , regardless of the body surface area.",
"        <br>",
"         &yen; The reversal of methotrexate action by leucovorin is competitive. Therefore, proportionately higher leucovorin concentrations are required to achieve rescue in the presence of high methotrexate levels. Specific dose modification schemas for leucovorin vary widely among protocols and institutions, but most schemas utilized are derived from Bleyer WA",
"         <sup>",
"          [4,5]",
"         </sup>",
"         . Refer to UpToDate topic on \"Therapeutic use and toxicity of high dose methotrexate\" for further information on leucovorin rescue and UpToDate table titled \"Recommendations for dose adjustment of leucovorin (d,l-racemic mixture) for prolonged methotrexate excretion\" as an example of leucovorin dose adjustment.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Children's Oncology Group - Protocol AOST0331 (EURAMOS1): A phase III intergroup study; a randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy (file://www.clinicaltrials.gov/ct2/show/NCT00134030?term=AOST0331&amp;rank=1, accessed December 17, 2012).",
"      </li>",
"      <li>",
"       Platinol (cisplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed November 20, 2012).",
"      </li>",
"      <li>",
"       Meyers PA, et al. J Clin Oncol 2005; 23:2004.",
"      </li>",
"      <li>",
"       Bleyer WA. Cancer Treat Rev 1977; 4:87.",
"      </li>",
"      <li>",
"       Bleyer WA. Cancer 1978; 41:36.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20800=[""].join("\n");
var outline_f20_20_20800=null;
var title_f20_20_20801="Trigeminal nerve danger zones";
var content_f20_20_20801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Danger zones for supraorbital, supratrochlear, infraorbital, and mental branches of the trigeminal nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trigeminal nerve danger zones. The supraorbital and supratrochlear nerves (area 1). The infrarobital nerve (area 2). The mental nerve (area 3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20801=[""].join("\n");
var outline_f20_20_20801=null;
var title_f20_20_20802="Gastric duplication cyst";
var content_f20_20_20802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal gastric duplication cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of the abdomen shows an echogenic mass pressing on the stomach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20802=[""].join("\n");
var outline_f20_20_20802=null;
var title_f20_20_20803="Dermoid cyst inflamed";
var content_f20_20_20803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflamed dermoid cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous nodule is present on the temple.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20803=[""].join("\n");
var outline_f20_20_20803=null;
var title_f20_20_20804="Uterine fibroids";
var content_f20_20_20804=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Uterine fibroids (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/20/20804/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20804/contributors\" id=\"au5051\">",
"       Elizabeth A Stewart, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/20/20804/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20804/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?20/20/20804/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20804/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?20/20/20804?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FIBROIDS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Fibroids are growths of the uterus, or womb [",
"     <a class=\"abstract\" href=\"UTD.htm?20/20/20804/abstract/1\">",
"      1",
"     </a>",
"     ] (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). They are also called uterine leiomyomas or myomas. The uterus is made of muscle, and fibroids grow from the muscle. Fibroids can bulge from the inside or outside of the uterus (",
"     <a class=\"graphic graphic_figure graphicRef64122 \" href=\"UTD.htm?2/31/2548\">",
"      figure 2",
"     </a>",
"     ). Fibroids are not cancerous and are not thought to be able to become cancerous.",
"    </p>",
"    <p>",
"     Fibroids are very common. Approximately 80 percent of women have fibroids, although not all of these women have bothersome fibroid symptoms. Treatments are available for women who have fibroid-related problems like heavy menstrual bleeding, pain or pressure in the pelvis, or problems with pregnancy or infertility.",
"    </p>",
"    <p>",
"     More detailed information about fibroids is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"      \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      FIBROID CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The cause of fibroids is unknown. Fibroids seem to respond to the female hormones estrogen and progesterone; some women have specific genes that may predispose them, and their families, to fibroids, and lifestyle and reproductive factors influence fibroids. Some fibroids grow with time and others shrink. Fibroids can also have growth spurts where they grow quickly over a short period of time. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"      \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      FIBROID SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Fibroids can range in size from microscopic to the size of a grapefruit or even larger. The majority of fibroids are small and do not cause any symptoms at all. However, some women with fibroids have very heavy or long menstrual periods or pelvic pressure or pain that interferes with their life.",
"    </p>",
"    <p>",
"     Fibroids are more likely to cause symptoms if the fibroids are large, if there are many fibroids, or if the fibroid is located in certain places in the uterus. Fibroid symptoms tend to get better when a woman no longer has menstrual periods, at menopause.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Increased menstrual bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fibroids can increase the amount and number of days of menstrual bleeding. Women who have excessive menstrual bleeding are at risk for a low blood count (iron deficiency anemia).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pelvic pressure and pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Larger fibroids can cause a sense of pelvic pressure or fullness in the abdomen, similar to the feeling of being pregnant. Sometimes women can even look pregnant when they are not due to the fibroids.",
"    </p>",
"    <p>",
"     Fibroids can also cause other symptoms, depending upon where they are located in the uterus. As an example, if a fibroid is pressing on the bladder, the woman may feel like she needs to go to the bathroom frequently. Similarly, a fibroid pressing on the rectum can cause constipation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Problems with fertility and pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women with fibroids are able to become pregnant without a problem. However, certain fibroids that distort the inside of the uterus can cause trouble becoming pregnant or with miscarriage. Women with fibroids and reproductive problems should go through a basic infertility evaluation before concluding the fibroids are responsible for the problem. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"      \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most women with fibroids have a completely normal pregnancy without complications. However, women with a large fibroid (greater than 5 to 6 cm) might have an increased risk of specific pregnancy complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link\">",
"      \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      FIBROID DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     A doctor or nurse may suspect fibroids if your uterus is enlarged or has an irregular shape. A pelvic ultrasound is needed to confirm that fibroids are present. Ultrasound uses sound waves to create a picture of the uterus.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      FIBROID TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Women who have no symptoms from their fibroids do not need to have treatment. Women with significant symptoms may try medical or surgical treatment. The best treatment depends on which symptom is most bothersome. The size, number and locations of fibroids also factor into most treatment decisions. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"      \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      MEDICAL FIBROID TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Medical treatments are those that use a medicine to reduce the heavy menstrual bleeding, which is common in women with fibroids. Medical treatments are often recommended before surgical treatments.",
"    </p>",
"    <p>",
"     There are a number of medical treatments available, including some that use hormones and some that do not.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Hormonal birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hormonal methods of birth control include the pill, skin patch, vaginal ring, shot, hormonal IUD, and implant. These treatments reduce bleeding, cramps, and pain during your menstrual period. It might take three months for bleeding to improve after you start taking hormonal birth control.",
"    </p>",
"    <p>",
"     More detailed information about hormonal birth control is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pills, patch, vaginal ring &mdash; Most forms of hormonal birth control, including the pill, skin path, and vaginal ring, are designed to be used for three weeks in a row, followed by one week off. During the fourth week, you will have menstrual bleeding. It might take three months for bleeding to improve after you start taking hormonal birth control.",
"       <br/>",
"       <br/>",
"       More information about hormonal birth control is available separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Some doctors and nurses advise women with heavy menstrual periods to take hormonal birth control continuously, without a break week. This will allow you to skip your period. This strategy is called continuous dosing.",
"       <br/>",
"       <br/>",
"       You can also take other types of hormonal birth control continuously. This is explained in detail separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link&amp;anchor=H15#H15\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\", section on 'Continuous dosing'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Hormonal intrauterine device &mdash; There is an intrauterine device (IUD) that slowly releases a form of a progesterone-like hormone called a progestin, into the uterus. There is no estrogen in the IUD. The IUD prevents pregnancy and reduces menstrual bleeding for up to five years. A doctor or nurse places the IUD inside the uterus. This treatment is best for women who do not have plans to become pregnant within the next 6 to 12 months. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link&amp;anchor=H3#H3\">",
"        \"Patient information: Long-term methods of birth control (Beyond the Basics)\", section on 'Intrauterine device (iud)'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Implant &mdash; There is an implant that slowly releases a progestin into your bloodstream. It prevents pregnancy and reduces menstrual bleeding for up to three years. A doctor or nurse places the implant (which is about the size of a match stick) under the skin in the upper inner arm. It is called Implanon&reg; in the US and elsewhere. This treatment is best for women who do not have plans to become pregnant within the next 6 to 12 months. The most common side effect of the progestin implant is irregular menstrual bleeding. For more detailed information, (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link&amp;anchor=H23#H23\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\", section on 'Birth control implant'",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Shot &mdash; Depot medroxyprogesterone acetate is a long-acting form of a progesterone-like hormone called a progestin. It is a shot given once every three months. This treatment prevents pregnancy and can reduce heavy menstrual bleeding. The shot is best for women who do not have plans to become pregnant in the next 6 to 12 months.",
"       <br/>",
"       <br/>",
"       The most common side effect of medroxyprogesterone acetate is bleeding and spotting, particularly during the first few months. Many women completely stop having menstrual periods after using this treatment for one year. More detailed information about medroxyprogesterone acetate is available separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link&amp;anchor=H19#H19\">",
"        \"Patient information: Hormonal methods of birth control (Beyond the Basics)\", section on 'Injectable birth control'",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Antifibrinolytic medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antifibrinolytic medicines can help to slow menstrual bleeding quickly. These medicines work by helping blood to clot. Antifibrinolytic medicines do not shrink fibroids or correct anemia. Tranexamic acid (Lysteda&reg;) is approved by the United States Food and Drug Administration for the indication of heavy menstrual bleeding.",
"    </p>",
"    <p>",
"     The advantages of antifibrinolytic medicines over other medical treatments are that:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The medicine slows bleeding quickly (within two to three hours)",
"      </li>",
"      <li>",
"       You need to take the medicine only during your period",
"      </li>",
"      <li>",
"       The medicines do not affect your chances of becoming pregnant",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Side effects can include headache and muscle cramps or pain. You should not take antifibrinolytic medicines with hormonal birth control unless your doctor or nurse approves; there may be an increased risk of blood clots, stroke, and heart attack when taken together.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs, such as ibuprofen (sold as Motrin&reg; or Advil&reg;) and naproxen (sold as Naprosyn or Alleve&reg;), can help reduce menstrual cramps. You can buy some NSAIDs (including ibuprofen) without a prescription.",
"    </p>",
"    <p>",
"     NSAIDs are not expensive, have few side effects, reduce pain, and you only need to take them during your menstrual period. You can take NSAIDs in combination with any of the medical treatments discussed here. However, NSAIDs do not reduce bleeding as well other medical treatments do.",
"    </p>",
"    <p>",
"     For women do not get relief with non-prescription NSAIDs, there are other similar medications available by prescription that may be helpful for some women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Gonadotropin-releasing hormone agonists",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gonadotropin-releasing hormone (GnRH) agonists are a medicine given by injection once every one to three months that can be used to temporarily shrink uterine fibroids and temporarily stop menstrual bleeding.",
"    </p>",
"    <p>",
"     GnRH agonists work by \"turning off\" the ovaries, causing a temporary and reversible menopause. &nbsp;If you are scheduled to have your fibroids removed surgically, your doctor might recommend that you first use GnRH agonists for 3 to 6 months to shrink the fibroids, which can make them easier to remove. This treatment is not routinely recommended for longer than six months in a row due to the risk of thinning bones when used for long periods of time. However, once the medication shrinks the fibroids, the medicine can be continued long-term, as long as low doses of estrogen and progestin are added to protect the bones. GnRH agonists do not work immediately. They first cause an increase in ovarian hormones that can cause an increase in symptoms for the first few weeks. This &ldquo;flare&rdquo; can be a problem for women with heavy bleeding who are severely anemic.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5259856\">",
"     <span class=\"h2\">",
"      Iron and vitamins",
"     </span>",
"     &nbsp;&mdash;&nbsp;For women who are anemic, the combination of iron supplements and a multivitamin, which will help the body effectively use the iron, is a an effective treatment option.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SURGICAL FIBROID TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Your doctor might recommend a surgical treatment for fibroids if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       You have fibroid-related heavy menstrual bleeding, pain, or pressure that does not get better with medical treatments",
"      </li>",
"      <li>",
"       You are trying to get pregnant and fibroids could be interfering",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Myomectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Myomectomy is a surgery done to remove fibroids which can reduce both bleeding and size related symptoms. Most women who have myomectomy are able to have children afterwards. However, there is a risk that fibroids will come back after myomectomy; between 10 and 25 percent of women who have myomectomy will need a second fibroid surgery. For this reason, myomectomy is not the best choice for women who do not want future pregnancies.",
"    </p>",
"    <p>",
"     There are several ways to perform myomectomy; the \"best\" way depends on where your fibroids are located and the size and number of fibroids (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"      \"Prolapsed uterine leiomyoma (fibroid)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link\">",
"      \"Abdominal myomectomy\"",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Abdominal myomectomy &mdash; This surgery requires an incision (cut) in the lower stomach to remove the fibroids.",
"      </li>",
"      <li>",
"       Laparoscopic or robotic myomectomy &mdash; This surgery uses several small incisions in the stomach. A doctor uses thin instruments and a camera (laparoscope) to remove the fibroids. Robotic myomectomy is a variation of laparoscopic myomectomy where the surgical procedure is aided with a surgical robot.",
"      </li>",
"      <li>",
"       Hysteroscopic myomectomy &mdash; If the fibroids are inside the opening of the uterus, a doctor can insert instruments through the cervix to remove the fibroids. This procedure helps more with heavy menstrual bleeding and not with size-related complaints.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Endometrial ablation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Endometrial ablation destroys the lining of the uterus. The treatment does not shrink the fibroid(s) but can help to decrease heavy menstrual bleeding caused by fibroids. In fact, some women who have endometrial ablation stop having menstrual periods.",
"    </p>",
"    <p>",
"     Ablation can be done in the office or as a day surgery. It can be done in combination with other treatments, such as myomectomy. Endometrial ablation is not a form of birth control, but pregnancy is not recommended after treatment. You will need to use some form of birth control to prevent pregnancy after ablation. Women who do get pregnant following ablation are more likely to have an abnormal pregnancy outside the uterus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Uterine artery embolization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Uterine artery embolization (also called UAE or uterine fibroid embolization, UFE) is a treatment that blocks the blood supply to fibroids. This causes the fibroid to shrink within weeks to several months after the treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link\">",
"      \"Uterine leiomyoma (fibroid) embolization\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The treatment is performed in the hospital after you are given light anesthesia or sedation. A doctor will insert a small tube into a large blood vessel in the inner thigh. The tube is threaded up to blood vessels near a fibroid (",
"     <a class=\"graphic graphic_figure graphicRef75866 graphicRef54882 \" href=\"UTD.htm?12/17/12563\">",
"      figure 3A-B",
"     </a>",
"     ). The doctor injects tiny particles into the blood vessel, which stops blood flow to the fibroid.",
"    </p>",
"    <p>",
"     To minimize pain after the treatment, most women stay in the hospital overnight. Pregnancy is not usually recommended after uterine artery embolization, although it is possible to become pregnant. Some form of birth control is recommended if you do not want to become pregnant.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21902046\">",
"     <span class=\"h2\">",
"      Magnetic resonance guided focused ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;Magnetic resonance guided focused ultrasound surgery (MRgFUS or FUS) (eg, ExAblate&reg; 2000) is a more recent fibroid treatment option. This noninvasive treatment takes place in a MRI machine which guides the treatment. Multiple waves of ultrasound energy go through the abdominal wall and converge on a small volume of tissue, which leads to thermal destruction of the fibroid. Women do receive sedation during the procedure and it can be performed as an outpatient procedure. Pregnancy is not usually recommended following FUS, although it is possible to become pregnant following treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Hysterectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hysterectomy is a surgery that removes the uterus. The ovaries and cervix are sometimes removed, along with the uterus.",
"    </p>",
"    <p>",
"     Hysterectomy is a permanent treatment that cures heavy menstrual bleeding and the bulk related symptoms of fibroids. However, it is major surgery, and you will need up to six weeks to fully recover. More detailed information about hysterectomy is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"      \"Patient information: Vaginal hysterectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHICH TREATMENT IS RIGHT FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     There are many treatments for fibroids, and it can be hard to decide which one is right. You should choose a treatment based upon your fibroid-related symptoms.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you are bothered by heavy menstrual bleeding, you can first try the medical treatments. Hormonal birth control, nonsteroidal antiinflammatory drugs (NSAIDs), or antifibrinolytic medicines work better than other medical treatments.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some women who no longer want future pregnancies can also be treated with endometrial ablation to reduce bleeding (see",
"     <a class=\"local\" href=\"#H16\">",
"      'Endometrial ablation'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     If medical treatment or endometrial ablation are not good options for you, or you also have symptoms related to the size of the fibroids, you can consider uterine fibroid embolization, myomectomy, hysterectomy or focused ultrasound surgery.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you are having trouble getting pregnant and fibroids could be the cause, myomectomy is the standard surgical option. Talk to your doctor to be sure that other possible causes of infertility have been addressed before you have fibroid surgery.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498629204\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3358128\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=see_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/62/20450?source=see_link\">",
"      Patient information: Repeated miscarriage (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/21/2386?source=see_link\">",
"      Patient information: Uterine artery embolization (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=see_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/13/25810?source=see_link\">",
"      Patient information: Uterine adenomyosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3358178\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"      Patient information: Vaginal hysterectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"      An overview of endometrial ablation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link\">",
"      Uterine leiomyoma (fibroid) embolization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12346?source=see_link\">",
"      Abdominal myomectomy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/uterinefibroids.html\">",
"      www.nlm.nih.gov/medlineplus/uterinefibroids.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       US Department of Health and Human Services",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.womenshealth.gov/FAQ/uterine-fibroids.cfm\">",
"      www.womenshealth.gov/FAQ/uterine-fibroids.cfm",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?20/20/20804?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Stewart, EA. Uterine Fibroids: The Complete Guide, Johns Hopkins University Press, Baltimore MD 2007.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f20_20_20804=[""].join("\n");
var outline_f20_20_20804=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FIBROIDS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           FIBROID CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           FIBROID SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           FIBROID DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           FIBROID TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           MEDICAL FIBROID TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SURGICAL FIBROID TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHICH TREATMENT IS RIGHT FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/31/2548\" title=\"figure 2\">",
"           Fibroid anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/8/34959\" title=\"figure 3A\">",
"           Fibroid embolization 1 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/51/15167\" title=\"figure 3B\">",
"           Fibroid embolization 2 PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f20_20_20805="Reactive node vs FL";
var content_f20_20_20805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reactive lymph node versus follicular lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: lymph node with reactive follicular hyperplasia. Discrete follicles, well separated by interfollicular tissue, are disposed predominantly in the cortex. Right panel: lymph node from a patient with follicular lymphoma, showing uniform nodularity throughout the node and little variation in size and shape of the follicles, which show a back-to-back arrangement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20805=[""].join("\n");
var outline_f20_20_20805=null;
var title_f20_20_20806="Suction vulva hematoma";
var content_f20_20_20806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Suction/irrigation system for debridement of large vulvar hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20806=[""].join("\n");
var outline_f20_20_20806=null;
var title_f20_20_20807="T cell receptor signaling";
var content_f20_20_20807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    T cell receptor signaling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A schematic representation of the pathways activated after ligation of the TCR as well as some of the molecules involved in this process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20807=[""].join("\n");
var outline_f20_20_20807=null;
var title_f20_20_20808="Photoaging histology";
var content_f20_20_20808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Comparison of photodamaged and normal skin on histologic examination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sun-protected skin.",
"    <br/>",
"    (B) Photoaged skin.",
"    <br/>",
"    Photoaged skin shows atypical keratinocytes, flattening of dermal papillae, and deposition of amorphous basophilic material (solar elastosis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20808=[""].join("\n");
var outline_f20_20_20808=null;
var title_f20_20_20809="Antimalarial drugs: An overview";
var content_f20_20_20809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antimalarial drugs: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Mark Travassos, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Miriam K Laufer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20809/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/20/20809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness (",
"    <a class=\"graphic graphic_figure graphicRef79113 \" href=\"UTD.htm?18/53/19288\">",
"     figure 1",
"    </a>",
"    ). The extent of pre-erythrocytic (hepatic stage) activity for most antimalarial drugs is not well characterized.",
"   </p>",
"   <p>",
"    Treatment of the acute blood stage infection is necessary for malaria caused by all malaria species. In addition, for infection due to Plasmodium ovale or P. vivax, terminal prophylaxis is required with a drug active against hypnozoites (which can remain dormant in the liver for months -- and occasionally years -- after the initial infection). The indications, availability, and relative cost for the drugs discussed in this overview are outlined in the Tables (",
"    <a class=\"graphic graphic_table graphicRef63936 \" href=\"UTD.htm?4/43/4797\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanisms of action, resistance and toxicities of antimalarial drugs will be reviewed here. Use of these agents for prevention and treatment of malaria is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"     \"Treatment of uncomplicated falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     QUINOLINE DERIVATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quinoline derivatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , amodiaquine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    , lumefantrine and halofantrine. These drugs have activity against the erythrocytic stage of infection; primaquine also kills intrahepatic forms and gametocytes (",
"    <a class=\"graphic graphic_figure graphicRef79113 \" href=\"UTD.htm?18/53/19288\">",
"     figure 1",
"    </a>",
"    ). The drugs act by accumulating in the parasite food vacuole and forming a complex with heme that prevents crystallization in the plasmodium food vacuole. Heme polymerase activity is inhibited, resulting in accumulation of cytotoxic free heme.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     4-aminoquinolines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Chloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    was the first drug produced on a large scale for treatment and prevention of malaria infection. Chloroquine has activity against the blood stages of Plasmodium ovale, P. malariae, and susceptible strains of P. vivax and P. falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/1\">",
"     1",
"    </a>",
"    ]. Widespread resistance in most malaria-endemic countries has led to decline in its use for the treatment of P. falciparum, although it remains effective for treatment of P. ovale, P. malariae, and, in most regions, P. vivax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=see_link\">",
"     \"Overview of non-falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    penetrates into most tissues and therefore has a large volume of distribution. As a result, serum drug levels may be maintained for up to two months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/2\">",
"     2",
"    </a>",
"    ]. Side effects of chloroquine include headaches, dizziness, abdominal discomfort, vomiting, and diarrhea. Chloroquine may also produce pruritus in some patients; this has been noted to occur most frequently in African populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/3\">",
"     3",
"    </a>",
"    ]. The pruritus is transient, lasting 48 to 72 hours, and is not responsive to antihistamines.",
"   </p>",
"   <p>",
"    Severe adverse reactions are extremely rare. Some are associated only with prolonged use, such as neuromyopathy with long-term prophylaxis and retinopathy with high-dose administration for treatment of rheumatologic diseases (total doses of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    or prophylaxis for greater than one year). Rare cases of idiosyncratic reactions, such as erythema multiforme and bone marrow toxicity, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    is only administered orally; intravenous infusion is associated with significant toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -resistant parasites, there is decreased accumulation of drug within the food vacuole. Mutations in the gene encoding the chloroquine resistance transporter protein (PfCRT), located in the food vacuole, are associated with chloroquine resistance both in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Tracing the spread of this gene mutation has led to the current understanding that chloroquine resistance developed independently in several locations in Asia, Papua New Guinea, and South America. The chloroquine-resistant gene that emerged in Southeast Asia spread across the Asian continent and reached Africa in the late 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Mutations in the homolog of the major multidrug-transporter Plasmodium falciparum multidrug resistance protein-1 (pfmdr1) may modulate the extent of chloroquine resistance as well as resistance to other antimalarials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    is used in some areas for treatment of chloroquine-resistant P. falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one study including 378 children with uncomplicated P. falciparum infection in Guinea-Bissau, the efficacy of double-dose chloroquine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     artemether-lumefantrine",
"    </a>",
"    was comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/12\">",
"     12",
"    </a>",
"    ]. Further study is needed to evaluate the efficacy of these agents in combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Amodiaquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amodiaquine is similar in structure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , and there is cross resistance between the two drugs, although amodiaquine retains some activity against chloroquine resistant parasites in vivo and in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amodiaquine has been taken off the market in the United States due to the risk of toxicity associated with prolonged administration for prophylaxis. The most serious adverse effects of amodiaquine are agranulocytosis and hepatotoxicity, which have been reported in European travelers using amodiaquine to prevent malaria. Based on prescription data from the United Kingdom, the frequency of neutropenia with amodiaquine prophylaxis was 1:2200, while that of hepatic toxicity was 1:15,650 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/16\">",
"     16",
"    </a>",
"    ]. Case reports have linked such adverse events with total doses of amodiaquine in excess of 1.5 g or with administration over at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amodiaquine is commonly used in malaria endemic countries as one of the few drugs available to treat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -resistant infections and is available in co-formulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/19\">",
"     19",
"    </a>",
"    ]. Amodiaquine is well tolerated when administered as a single course of treatment over three days. Trials evaluating a three-day treatment course of amodiaquine for uncomplicated malaria noted mild to moderate adverse effects (including nausea, emesis, and pruritus), with no significant hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. Adverse event rates were the same as other commonly used antimalarial drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Declines in neutrophil counts below",
"    <span class=\"nowrap\">",
"     1000/mm3",
"    </span>",
"    have been noted with amodiaquine used for therapy of malaria infection, although the clinical significance is not certain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk for adverse effects related to amodiaquine may be increased in patients with HIV infection. Among 160 children with malaria treated with amodiaquine-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    therapy, risk of neutropenia was higher among HIV-positive children than HIV-negative children, particularly among patients receiving antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     4-methanolquinolines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Quinine and quinidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    is a derivative from the bark of the South American Cinchona tree and exists in oral and parenteral forms. In malaria-endemic regions it is the most commonly used parenteral antimalarial drug, and in many regions it is the only available agent for severe malaria, although in the United States quinine is only available in its oral form.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    is a stereoisomer of quinine available in parenteral formulation and is very effective for treatment of severe malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    include a complex of symptoms referred to as cinchonism: tinnitus, nausea, headaches, dizziness and disturbed vision. These effects are observed to some extent in all patients receiving treatment and typically resolve with cessation of the medication. These symptoms do not warrant change in drug dose. However, toxicity often interferes with compliance in completing the course of therapy. Less commonly, hypersensitivity reaction with bronchospasm and cutaneous manifestations, such as flushing and urticaria, may occur.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    has a short half-life. When given orally it must be administered three times per day; when administered together with one week of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotics or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , the duration of therapy is three to seven days. The drug should be given for seven days if the infection is acquired in an area where decreased quinine susceptibility has been reported, such as Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For severe disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    can be administered intravenously or intramuscularly. Intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and quinine should be as an infusion because rapid boluses are associated with hypotension. To hasten parasite clearance time, an initial loading dose of parenteral quinine or quinidine is appropriate if the patient has not received treatment with these agents recently [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/26\">",
"     26",
"    </a>",
"    ]. After initial improvement on parenteral therapy, patients can be switched to oral medication. Therapeutic approaches include completing a course of oral quinine plus an antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ), or a full course of another oral antimalarial with better tolerability than quinine. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Antimicrobials'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    have a narrow therapeutic window; overdosage may lead to cardiotoxicity, including arrhythmias and hypotension, blindness or deafness. Quinidine is the more cardiotoxic of these agents: cardiac monitoring including serial blood pressure measurements should always be in place when quinidine is administered, to monitor for prolongation of the QT interval and ventricular tachycardia. Blood sugar levels should be monitored with intravenous infusion, as both quinine and quinidine stimulate insulin production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    efficacy has been described in Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/25\">",
"     25",
"    </a>",
"    ]. The mechanism for quinine resistance is complex and poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/28\">",
"     28",
"    </a>",
"    ]. The combination of quinine with an antibiotic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ) remains effective in areas where decreased quinine susceptibility has been observed.",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    is no longer used routinely as an anti-arrhythmic medication in the United States, it may not be readily available; in such circumstances the manufacturer Eli Lilly may be contacted directly to arrange shipment (telephone 800-821-0538).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mefloquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    is available as an oral formulation and may be used as treatment or prophylaxis for all susceptible malaria species.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    include vomiting and dizziness. Like the other drugs in this class, mefloquine can also interfere with cardiac conduction and therefore should not be used in individuals with cardiac conduction abnormalities.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    is contraindicated for individuals with neurologic and psychiatric disorders; those with significant family history of seizures and major psychiatric disorders should also avoid taking mefloquine. Seizures, encephalopathy and psychosis occur in 0.1 to 5 percent of patients treated for malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/29\">",
"     29",
"    </a>",
"    ]. The extent to which mefloquine is associated with serious neuropsychiatric side effects in the setting of weekly prophylaxis is an area of controversy. The risk of psychosis and panic attacks with mefloquine compared to other antimalarials is increased twofold, although the absolute risk is low (one to three episodes per 1000 person-years of exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. There is no evidence of an increased risk of depression compared to other antimalarials. Mefloquine users may experience sleep disturbances, including strange dreams and insomnia, but at rates comparable with other antimalarial medications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    -induced pneumonitis is an infrequently reported but serious adverse event in the setting of both prophylactic and therapeutic use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. One-third of the patients improved following treatment with corticosteroids, and most patients fully recovered upon discontinuation of the drug.",
"   </p>",
"   <p>",
"    Splitting the 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose into 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over a 6 to 24 hour period may be helpful to reduce mild adverse effects. When used for prophylaxis it is best started two to three weeks prior to departure to assess tolerability, though side effects can develop long into the prophylactic course or even if it has been well tolerated in the past.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    resistance is found primarily in Thailand (where the drug was used as monotherapy in the 1980s). Mefloquine treatment failure is associated with an increase in copy number of the pfmdr1, the homolog of the major multidrug-transporter. This encodes a protein on the digestive vacuole membrane that appears to play a role in regulating traffic across the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/37\">",
"     37",
"    </a>",
"    ]. The combination of mefloquine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    appears to be effective in most regions of Southeast Asia. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Artemisinin derivatives'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     8-aminoquinolines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Primaquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    is the only 8-aminoquinoline in clinical use; its mechanism of action is not known. Largely it is used to prevent relapse of P. ovale and P. vivax malaria by eliminating dormant hypnozoites, and it also has activity against the pre-erythrocytic stage and gametocytes of P. falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     Primaquine",
"    </a>",
"    can cause hemolytic anemia in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, patients should receive primaquine only if G6PD deficiency has been excluded. Primaquine may also cause gastrointestinal upset that can be minimized if taken with food. Primaquine is contraindicated in pregnancy and breastfeeding.",
"   </p>",
"   <p>",
"    Hypnozoite resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    is difficult to assess. Parasitemia within the first four to six weeks of an initial infection may be due to failure of the blood stage treatment, inadequate adherence, or primaquine failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lumefantrine and halofantrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumefantrine and halofantrine are similar in structure to the 4-methanolquinolines. These drugs are active against most",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -resistant parasites, although there is cross-resistance between halofantrine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Lumefantrine is a long-acting partner drug to artemether in a widely used fixed-dose combination; the half-life of lumefantrine is 3 to 6 days. An important determinant of lumefantrine efficacy is drug level; the oral bioavailability is highly variable and increases up to three- to fourfold when taken with a high fat meal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumefantrine is well tolerated, with rare mild adverse reactions such as diarrhea, nausea, abdominal pain, and vomiting. There is no evidence of significant cardiotoxicity associated with lumefantrine use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Halofantrine has been effective in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    -resistant malaria, although cardiac toxicity (dose-dependent prolongation of the PR and QTc intervals) limits its use, and it is not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTIFOLATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifolates include sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    , proguanil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    . These drugs act synergistically to target enzymes involved in folate synthesis, a pathway required for parasite DNA synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sulfadoxine-pyrimethamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfadoxine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    target enzymes involved in folate synthesis; pyrimethamine targets dihydrofolate reductase (DHFR), and sulfadoxine acts on dihydropteroate synthase (DHPS) (",
"    <a class=\"graphic graphic_figure graphicRef71984 \" href=\"UTD.htm?19/11/19647\">",
"     figure 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     Sulfadoxine-pyrimethamine",
"    </a>",
"    (SP; brand name Fansidar) is available in a fixed-dose tablet; because the components act on enzymes in the same pathway, it is not considered a combination therapy.",
"   </p>",
"   <p>",
"    Mild adverse effects include gastrointestinal upset and headache. Mild bone marrow suppression may occur, and sulfadoxine can precipitate hemolysis in patients with G6PD deficiency. Severe cutaneous toxicity due to the sulfa moiety can occur, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    occurs via mutations in the target enzymes DHFR and DHPS. P. falciparum resistance to sulfadoxine-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    is widespread in most malaria-endemic regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atovaquone-proguanil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    interferes with two separate pathways involved in the biosynthesis of pyrimidines that are essential for nucleic acid replication.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    blocks the parasite mitochondrial electron transport chain, and proguanil inhibits parasite dihydrofolate reductase through its active metabolite, cycloguanil. Proguanil also appears to act via a direct mechanism outside the folate pathway, enhancing atovaquone's mitochondrial membrane toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects include abdominal pain, vomiting, diarrhea, headache and pruritis. Among adults in Thailand, mild asymptomatic increases in transaminases were observed shortly after initiating therapy, although they normalized by day 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    is mediated by mutations in the cytochrome b gene. The polymorphism associated with resistance has been found in parasite populations even in the absence of drug pressure, and can arise rapidly when the drug is used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, the combination retains excellent clinical efficacy for treatment and prevention throughout the world even in the presence of antifolate resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANTIMICROBIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    target prokaryotic protein synthesis. In malaria parasites, these drugs appear to target the apicoplast, an organelle derived from prokaryotic ancestors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/47\">",
"     47",
"    </a>",
"    ]. Antimicrobials have relatively slow antimalarial activity because they exert their toxic effects in the subsequent cycle of cell division [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/47,58\">",
"     47,58",
"    </a>",
"    ]. They are typically paired with fast-acting antimalarials (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    ). Doxycycline has a longer half life than tetracycline so is used more commonly. Resistance has not been detected to tetracycline, doxycycline or clindamycin.",
"   </p>",
"   <p>",
"    Adverse effects are common with the tetracyclines and interfere with adherence. Gastrointestinal discomfort and candidiasis are the most frequent complaints.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    therapy also poses a risk of esophageal ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/59\">",
"     59",
"    </a>",
"    ]. Photosensitivity can occur with doxycycline, which can be concerning for fair-skinned travelers using it as prophylaxis for travel to the tropics.",
"   </p>",
"   <p>",
"    Tetracyclines should not be given to pregnant women or children less than 8 years old because of the risk of deposition in growing bones and teeth.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is the preferred alternative in these groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ARTEMISININ DERIVATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The artemisinins are derived from the leaves of the Chinese sweet wormwood plant, Artemisia annua. They have been used in China for the treatment of malaria for over 2000 years and came to attention outside of China in the 1970s and 1980s. Artemisinin formulations include artemether, arteether, dihydroartemisinin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    ; these are marketed predominantly in malaria-endemic countries.",
"   </p>",
"   <p>",
"    Artemisinins appear to act by binding iron, breaking down peroxide bridges leading to the generation of free radicals that damage parasite proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/60\">",
"     60",
"    </a>",
"    ]. They act rapidly, killing blood stages of all Plasmodium species and reducing the parasite biomass [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/61\">",
"     61",
"    </a>",
"    ]. Artemisinins have the fastest parasite clearance times of any antimalarial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/62\">",
"     62",
"    </a>",
"    ]. Artemisinins are active against gametocytes, the parasite form that is infectious to mosquitoes, and their use has been associated with reduced malaria transmission when they were introduced in Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    is used for the treatment of severe malaria. It is superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    for treatment of severe malaria with respect to clearing parasitemia and reducing mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Intravenous artesunate has been made available in the US through the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/67\">",
"     67",
"    </a>",
"    ]. Rectal artesunate is used in remote areas of malaria-endemic countries for stabilizing severely ill patients prior to health facility transport for further management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the short half-life of artemisinins, intravenous therapy must be followed by a longer acting agent once the patient is able to tolerate oral medication. If used alone (via the parenteral, rectal or oral route),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    must be administered for five to seven days. Treatment for less than five days results in recurrent parasitemia several weeks after therapy due to the very short duration of action, rather than to artemisinin resistance.",
"   </p>",
"   <p>",
"    Artemisinins are generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/63,69,70\">",
"     63,69,70",
"    </a>",
"    ]. Type 1 hypersensitivity to the artemisinin compounds has been reported (incidence 1:3000) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/71\">",
"     71",
"    </a>",
"    ]. A large-scale study on the adverse effects of orally-administered artemisinins demonstrated transient neurological abnormalities, including nystagmus and disturbances in balance; these effects resolved without lasting sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/70\">",
"     70",
"    </a>",
"    ]. Transient neutropenia has been observed in individuals receiving oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    at doses higher than that typically prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, artemisinin derivatives have not been found to be teratogenic in the second and third trimesters of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A limited number of women in their first trimester have been studied without evidence of adverse events. In animals,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    has been observed to induce abortions, cardiovascular malformations, and skeletal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced susceptibility to artemisinins, as evidenced by delayed parasite clearance time, has been demonstrated in western Cambodia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The underlying mechanism and its long term clinical implications are not known. Because the artemisinins are the cornerstone of nearly all new combination therapies, the WHO has called for the banning of all manufacturing and distribution of oral artemisinin monotherapy to deter resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Artemisinin-based combination therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, artemisinins should not be used as a single agent, to prevent emergence of drug resistance and to avoid the need for prolonged therapy. Artemisinin-based combination therapy (ACTs) combine the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. ACTs are typically administered for three days and are often available in fixed-dose tablets. Five ACTs are recommended by the WHO for the treatment of uncomplicated malaria:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     artemether-lumefantrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    -amodiaquine, artesunate-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    , artesunate-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    , and dihydroartemisinin-piperaquine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/79\">",
"     79",
"    </a>",
"    ]. Artemether-lumefantrine is the most widely adopted ACT in Africa, followed by artesunate-amodiaquine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/80\">",
"     80",
"    </a>",
"    ]. The combination artemether-lumefantrine, produced by Novartis under the trade name Coartem, has been approved by the US Food and Drug Administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Tafenoquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tafenoquine is an 8-aminoquinoline that is structurally similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    . It is active against liver stages of P. falciparum and P. vivax (including hypnozoites), asexual blood stage infection and gametocytes. It has a longer half-life than primaquine and is being evaluated as a prophylactic agent against P. falciparum and as a radical cure agent for P. vivax. As with primaquine, tafenoquine can induce hemolytic anemia in patients with G6PD deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pyronaridine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyronaridine was one of the first synthetically developed antimalarial drugs after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    . It is active against chloroquine-resistant infections both in vitro and in vivo, although there has been concern about the emergence of resistance if used as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. It is being developed as an artemisinin-based combination therapy in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/83\">",
"     83",
"    </a>",
"    ]. Pyronaridine-artesunate has been shown to have similar efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     artemether-lumefantrine",
"    </a>",
"    in the treatment of uncomplicated P. falciparum malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/84\">",
"     84",
"    </a>",
"    ]. Advantages of pyronaridine include its structural dissimilarity to other antimalarial drugs, long shelf-life and once-daily dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DRUG QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counterfeit and low quality antimalarial medications are significant concerns worldwide, with implications for treatment failure among individual patients and public health concerns related to development of drug resistance. In surveys of antimalarial medications purchased in Southeast Asia, 30 to 50 percent of medications were counterfeit, containing a subtherapeutic or undetectable amount of active ingredient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. These samples were purchased in a range of different venues, including informal shops, pharmacies, and hospitals. There is increasing evidence that the quality of antimalarial drugs in Africa is also substandard, especially those purchased outside the formal health care system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20809/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13746045\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness (",
"      <a class=\"graphic graphic_figure graphicRef79113 \" href=\"UTD.htm?18/53/19288\">",
"       figure 1",
"      </a>",
"      ). Treatment of the acute blood stage infection is necessary for malaria caused by all malaria species. The indications, availability, and relative cost for the drugs are outlined in the Tables (",
"      <a class=\"graphic graphic_table graphicRef63936 \" href=\"UTD.htm?4/43/4797\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of infection due to P. ovale or P. vivax, terminal prophylaxis is required with a drug active against hypnozoites, which can otherwise remain dormant in the liver for months to years after infection.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       Primaquine",
"      </a>",
"      is the only medication licensed for elimination of hypnozoites. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quinoline derivatives (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      , amodiaquine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      , lumefantrine, and halofantrine) have activity against the erythrocytic stage of infection; primaquine also kills intrahepatic forms and gametocytes (",
"      <a class=\"graphic graphic_figure graphicRef79113 \" href=\"UTD.htm?18/53/19288\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Widespread resistance in most malaria-endemic countries has led to decline in use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      for the treatment of P. falciparum, although it remains effective for treatment of P. ovale, P. malariae, and, in most regions, P. vivax. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chloroquine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      exists in oral and parenteral forms. In malaria-endemic regions it is the most commonly used parenteral antimalarial drug, and in many regions it is the only available agent for severe malaria, although in the United States quinine is only available in its oral form. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Quinine and quinidine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      is available as an oral formulation and may be used as treatment or prophylaxis for all susceptible malaria species. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mefloquine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       Primaquine",
"      </a>",
"      is used to prevent relapse of P. ovale and P. vivax malaria by eliminating dormant hypnozoites, and it also has activity against the pre-erythrocytic stage and gametocytes of P. falciparum. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Primaquine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antifolates (sulfonamides,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      , proguanil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      ) act synergistically to target enzymes involved in folate synthesis, a pathway required for parasite DNA synthesis (",
"      <a class=\"graphic graphic_figure graphicRef71984 \" href=\"UTD.htm?19/11/19647\">",
"       figure 2",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       Atovaquone-proguanil",
"      </a>",
"      interferes with two separate pathways involved in the biosynthesis of pyrimidines essential for nucleic acid replication. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antifolates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      target prokaryotic protein synthesis. They are typically paired with fast-acting antimalarials (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      is superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      for treatment of severe malaria with respect to clearing parasitemia and reducing mortality. Artemisinin-based combination therapy (ACTs) combine the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Artemisinin derivatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/1\">",
"      White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/2\">",
"      Warhurst DC, Steele JC, Adagu IS, et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003; 52:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/3\">",
"      EKPECHI OL, OKORO AN. A PATTERN OF PRURITUS DUE TO CHLOROQUINE. Arch Dermatol 1964; 89:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/4\">",
"      Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/5\">",
"      Severe and complicated malaria. World Health Organization Malaria Action Programme. Trans R Soc Trop Med Hyg 1986; 80 Suppl:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/6\">",
"      SCOTT V. Single intravenous injections of chloroquine in the treatment of falciparum malaria: toxic and immediate therapeutic effects in 110 cases. Am J Trop Med Hyg 1950; 30:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/7\">",
"      Djimd&eacute; A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/8\">",
"      Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/9\">",
"      Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/10\">",
"      Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/11\">",
"      Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/12\">",
"      Ursing J, Kofoed PE, Rodrigues A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis 2011; 203:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/13\">",
"      Kofoed PE, Ursing J, Poulsen A, et al. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans R Soc Trop Med Hyg 2007; 101:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/14\">",
"      Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002; 298:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/15\">",
"      Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003; :CD000016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/16\">",
"      Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/17\">",
"      Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/18\">",
"      Neftel KA, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986; 292:721.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/prequal/query/ProductRegistry.aspx (Accessed on February 13, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/20\">",
"      Olliaro P, Nevill C, LeBras J, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996; 348:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/21\">",
"      Massaga JJ, Lusingu JP, Makunde R, et al. Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania. Tanzan J Health Res 2008; 10:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/22\">",
"      Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/23\">",
"      Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/24\">",
"      Phillips RE, Warrell DA, White NJ, et al. Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med 1985; 312:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/25\">",
"      Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/26\">",
"      Lesi A, Meremikwu M. High first dose quinine regimen for treating severe malaria. Cochrane Database Syst Rev 2004; :CD003341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/27\">",
"      Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/28\">",
"      Ferdig MT, Cooper RA, Mu J, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol 2004; 52:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/29\">",
"      Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Int Health 2008; 13:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/30\">",
"      Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/31\">",
"      Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/32\">",
"      Katsenos S, Psathakis K, Nikolopoulou MI, Constantopoulos SH. Mefloquine-induced eosinophilic pneumonia. Pharmacotherapy 2007; 27:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/33\">",
"      Soentjens P, Delanote M, Van Gompel A. Mefloquine-induced pneumonitis. J Travel Med 2006; 13:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/34\">",
"      Inoue T, Tanaka E, Sakuramoto M, et al. [Case of drug-induced pneumonia possibly due to mefloquine (antimalarial drug)]. Nihon Kokyuki Gakkai Zasshi 2005; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/35\">",
"      Udry E, Bailly F, Dusmet M, et al. Pulmonary toxicity with mefloquine. Eur Respir J 2001; 18:890.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm120613.htm (Accessed on September 19, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/37\">",
"      Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/38\">",
"      Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/39\">",
"      White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/40\">",
"      Ezzet F, van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/41\">",
"      White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/42\">",
"      Makanga M, Premji Z, Falade C, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 2006; 74:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/43\">",
"      ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/44\">",
"      Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/45\">",
"      Matson PA, Luby SP, Redd SC, et al. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg 1996; 54:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Sudden death in a traveler following halofantrine administration--Togo, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/47\">",
"      Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 2007; 152:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/48\">",
"      Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/49\">",
"      Gimnig JE, MacArthur JR, M'bang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006; 74:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/50\">",
"      Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998; 54:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/51\">",
"      Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334.",
"     </a>",
"    </li>",
"    <li>",
"     GlaxoSmithKline. Malarone prescribing information. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/53\">",
"      Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/54\">",
"      Happi CT, Gbotosho GO, Folarin OA, et al. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J 2006; 5:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/55\">",
"      Schw&ouml;bel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/56\">",
"      Nakato H, Vivancos R, Hunter PR. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. J Antimicrob Chemother 2007; 60:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/57\">",
"      Krudsood S, Patel SN, Tangpukdee N, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2007; 76:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/58\">",
"      Dahl EL, Shock JL, Shenai BR, et al. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2006; 50:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/59\">",
"      Al-Mofarreh MA, Al Mofleh IA. Esophageal ulceration complicating doxycycline therapy. World J Gastroenterol 2003; 9:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/60\">",
"      Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/61\">",
"      White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/62\">",
"      White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/63\">",
"      Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/64\">",
"      Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/65\">",
"      Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/66\">",
"      Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Disease Control and Prevention. Artesunate now available to treat severe malaria in US. In: Centers for Disease Control and Prevention [electronic mail system]. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/68\">",
"      Gomes M, Ribeiro I, Warsame M, et al. Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis 2008; 8:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/69\">",
"      Myint HY, Tipmanee P, Nosten F, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 2004; 98:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/70\">",
"      Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/71\">",
"      Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001; 95:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/72\">",
"      Bethell D, Se Y, Lon C, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis 2010; 51:e105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/73\">",
"      McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 2001; 33:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/74\">",
"      Ward SA, Sevene EJ, Hastings IM, et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/75\">",
"      Clark RL, Lerman SA, Cox EM, et al. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res B Dev Reprod Toxicol 2008; 83:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/76\">",
"      Clark RL, Arima A, Makori N, et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol 2008; 83:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/77\">",
"      Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/78\">",
"      Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for the treatment of malaria, 2nd edition, WHO Press, Geneva 2010.",
"    </li>",
"    <li>",
"     World Health Organization. World malaria report 2009. WHO Press, Geneva 2009. file://whqlibdoc.who.int/publications/2009/9789241563901_eng.pdf (Accessed on December 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/81\">",
"      Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998; 26:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/82\">",
"      Vivas L, Rattray L, Stewart L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop 2008; 105:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/83\">",
"      Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008; 198:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/84\">",
"      Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010; 375:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/85\">",
"      Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/86\">",
"      Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet 2001; 357:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/87\">",
"      Newton PN, Fern&aacute;ndez FM, Plan&ccedil;on A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008; 5:e32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/88\">",
"      Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health 2007; 12:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20809/abstract/89\">",
"      Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008; 3:e2132.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 468 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20809=[""].join("\n");
var outline_f20_20_20809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13746045\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      QUINOLINE DERIVATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      4-aminoquinolines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Chloroquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Amodiaquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      4-methanolquinolines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Quinine and quinidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mefloquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      8-aminoquinolines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Primaquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lumefantrine and halofantrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTIFOLATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sulfadoxine-pyrimethamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atovaquone-proguanil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANTIMICROBIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ARTEMISININ DERIVATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Artemisinin-based combination therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INVESTIGATIONAL DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Tafenoquine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pyronaridine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DRUG QUALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13746045\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/468|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19288\" title=\"figure 1\">",
"      Malaria life cycle drug targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/11/19647\" title=\"figure 2\">",
"      Folate synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/43/4797\" title=\"table 1\">",
"      Antimalarial drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4394?source=related_link\">",
"      Overview of non-falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_20_20810="Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis";
var content_f20_20_20810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Philip S Hsu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Carmel Armon, MD, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Kerry Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/20/20810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/20/20810/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/20/20810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral radiculopathy is a condition in which a disease process affects the function of one or more lumbosacral nerve roots [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical aspects of lumbosacral radiculopathy will be reviewed here.",
"   </p>",
"   <p>",
"    The treatment of lumbosacral radiculopathy and other disorders of the lower spine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=see_link\">",
"     \"Acute lumbosacral radiculopathy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lumbar spine consists of five movable lumbar vertebral bodies, numbered L1 to L5 (",
"    <a class=\"graphic graphic_figure graphicRef66123 \" href=\"UTD.htm?29/5/29779\">",
"     figure 1",
"    </a>",
"    ). The sacrum is made up of five developmentally fused vertebral levels (S1 to S5), followed by a terminal bony prominence, the coccyx. The entire region is commonly described as the lumbosacral spine.",
"   </p>",
"   <p>",
"    Directly beneath each lumbar and sacral vertebra, there is a pair of neural foramina with the same number designation, such that the L1 neural foramina are located just below the L1 vertebral body. Neural foramina are bounded superiorly and inferiorly by pedicles, anteriorly by the intervertebral disc and vertebral body, and posteriorly by facet joints (",
"    <a class=\"graphic graphic_figure graphicRef66123 \" href=\"UTD.htm?29/5/29779\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Through each neural foramen passes the same numbered spinal nerve root, recurrent meningeal nerves, and radicular blood vessels. On each side there are five lumbar, five sacral, and one coccygeal spinal nerve roots.",
"   </p>",
"   <p>",
"    All lumbar and sacral spinal nerve roots originate at the T10 to L1 vertebral level, where the spinal cord ends as the conus medullaris. A dorsal (somatic sensory) root from the posterolateral aspect of the spinal cord and a ventral (somatic motor) root from the anterolateral aspect of the cord join in the spinal canal to form the spinal nerve root (",
"    <a class=\"graphic graphic_figure graphicRef66123 \" href=\"UTD.htm?29/5/29779\">",
"     figure 1",
"    </a>",
"    ). The roots then course down through the intraspinal canal, forming the cauda equina, until they exit at their respective neural (intervertebral) foramina. Thus, the lumbosacral nerve roots exit the spinal canal at a lower level than where they arise. A potential consequence of this arrangement is that intraspinal pathology may affect roots at higher levels than the level where the roots exit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cell bodies of the motor nerve fibers are located in the ventral (anterior) horns of the spinal cord, while those of the sensory nerve fibers are in a dorsal root ganglion at each lumbar and sacral level. Dorsal root ganglia (DRG) tend to be located within the neural foramina, and are therefore not strictly speaking intraspinal (ie, within the lumbar canal). However, at the low lumbar and sacral levels there is a tendency for DRG to reside proximal to the neural foramina, within the intraspinal canal, as found in 11 to 38 percent of cases at L5 and 71 percent at S1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The dorsal root ganglia are attached to the vertebral body on the transverse process [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/6\">",
"     6",
"    </a>",
"    ]. Compressive radicular disease typically occurs proximal to this.",
"   </p>",
"   <p>",
"    As noted above, the spinal cord normally terminates at the conus medullaris within the lumbar intraspinal canal between the T10 and L1 vertebral levels. Exceptions include patients with congenital spinal deformities known as spina bifida, in which the fetal conus is tethered to ligamentous or bony structures, causing lengthening of the spinal cord during development. In such patients, the conus medullaris can be displaced downward to the middle or lower lumbar spine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rami",
"    </span>",
"    &nbsp;&mdash;&nbsp;Just distal to the neural foramen, the nerve root divides in two, forming the dorsal and ventral primary rami.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The small dorsal (posterior) primary ramus supplies motor innervation to the paraspinal muscles and cutaneous innervation to the skin of the trunk and back",
"     </li>",
"     <li>",
"      The large ventral (anterior) primary ramus supplies motor and sensory innervation to the legs and trunk, including abdominal wall muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dorsal rami of the spinal nerves also supply the apophyseal joints and the paraspinal muscles. They innervate structures both above and below the level of the nerve. Clinical evaluation of injury to the dorsal rami is difficult because of the overlap in areas innervated by these nerves and because of the limited ability to clinically evaluate individual paraspinal muscles. However, electromyography can be helpful in determining the distribution of disease.",
"   </p>",
"   <p>",
"    The ventral rami innervate the extremities and the trunk. These branches can be evaluated by assessing the motor and sensory functions of the different myotomes and dermatomes, respectively. However, variability to the dermatomal and myotomal distribution of innervation exists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myotomes and dermatomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The collection of muscles with significant innervation from a single root is called a myotome. Similarly, the sensory distribution of a single root is labeled a dermatome.",
"   </p>",
"   <p>",
"    The primary manifestations of lumbosacral root disease can be broken up into dysfunction of two distinct systems: motor and sensory. Motor dysfunction from a root lesion may cause weakness in some or all muscles innervated by that root. However, many muscles have innervation from multiple roots, which may result in preserved strength despite significant involvement of a single root.",
"   </p>",
"   <p>",
"    Although there are classic descriptions for the distributions of myotomes and dermatomes, substantial variability exists in these distributions from person to person [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Sensory fields have considerable overlap, but there are areas that are exclusively served by individual nerves. These areas are called autonomous zones. The most important of these in the evaluation of lumbosacral radiculopathies include the sole of the foot (S1), dorsum of the foot (L5), medial calf (L4), and anterior thigh (L2 and 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lumbosacral myotomes are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef64209 \" href=\"UTD.htm?4/31/4605\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sinuvertebral nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sinuvertebral nerves are sensory nerves that innervate various structures within the spine, such as ligamentous structures, the dura, periosteum, and blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/10\">",
"     10",
"    </a>",
"    ]. They originate distal to the dorsal root ganglia and extend to communicate with branches from radicular levels both above and below the level of entry, as well as the contralateral side, making it difficult to localize pain from involvement of these nerves.",
"   </p>",
"   <p>",
"    Irritation of the sinuvertebral nerves may result in low back pain. Because they arise distal to the nerve root, however, involvement of sinuvertebral nerves or their branches without involvement of the rest of the nerve root is not considered to be radicular in nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common etiology of lumbosacral radiculopathy is nerve root compression caused by a disc herniation or spondylosis (ie, spinal stenosis due to degenerative arthritis affecting the spine). Additional etiologies include nonskeletal causes of nerve root compression and noncompressive mechanisms such as infection, inflammation, neoplasm, and vascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pain generators in the lumbosacral spine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of tissues making up the low back contain nerve fibers with pain receptors. These are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef76627 \" href=\"UTD.htm?9/4/9292\">",
"     table 2",
"    </a>",
"    ). Of note, intervertebral disc material does not contain significant numbers of pain fibers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic radiating pain from spinal nerve injury is mediated through proximal spinal nerves. Compression of a spinal nerve root by disc or arthritic spur leads to local edema, ischemia, and inflammation. These factors contribute to production of pain impulses through the spinal nerves. The pain from acute disc herniation or spondylotic spinal nerve entrapment reflects a combination of pain generation within the nerve root itself, as well as the pain from neighboring tissues whose pain fibers are activated by the effect of disc herniation on dura, ligaments, and surrounding vasculature.",
"     </li>",
"     <li>",
"      Localized lumbosacral pain is thought to arise from intraspinal structures. These pain impulses arise from the blood vessels, dura mater, and longitudinal ligaments, and travel in the sinuvertebral nerves through the neural foramina, connecting via rami communicantes with the extraspinal sympathetic chain.",
"     </li>",
"     <li>",
"      Nonlocalized, nonradiating pain is thought to arise from muscle, bone, and ligament outside the spinal canal. Interconnected ventral and dorsal nerve plexuses surround the vertebral column [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/11\">",
"       11",
"      </a>",
"      ]. The ventral nerve plexus serves the anterior longitudinal ligament and has bilateral innervation. Many branches from the sympathetic trunk, rami communicantes, and perivascular nerve plexuses join to form the ventral nerve plexus. The dorsal nerve plexus arises from the sinuvertebral nerves and serves the posterior longitudinal ligament.",
"     </li>",
"     <li>",
"      Referred spine pain may arise from the abdominal viscera that share the same spinal level of innervation. Organs that can potentially refer pain to the spine include the aorta, pancreas, duodenum, colon, rectum, kidney, ureter, bladder, and pelvic organs. Systemic illness can refer pain to the bony spine or can produce bony disease that generates spine pain. The major categories and clues to their diagnosis are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef69498 \" href=\"UTD.htm?40/1/40987\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Degenerative changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to spinal nerve roots occurs as the result of degenerative change involving three main structures, which are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The intervertebral discs",
"     </li>",
"     <li>",
"      The uncovertebral joints",
"     </li>",
"     <li>",
"      The zygapophyseal (facet) joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resulting bony overgrowth (osteophytes) or disc herniation at these points may directly impinge on spinal nerve roots or the spinal cord, or their effect may be primarily to produce instability and misalignment of the spine (ie, degenerative spondylolisthesis) that in turn produces pain and neurologic deficits. It is not known whether changes in these different structures are causally related or occur independently.",
"   </p>",
"   <p>",
"    Degenerative spondylotic changes are common with aging and usually do not result in radiculopathy. Low back pain associated with degenerative changes is distinct from radicular pain and is much more frequent. Given the inability to ascertain the exact cause, it is commonly referred to as nonspecific low back pain.",
"   </p>",
"   <p>",
"    One school of thought suggests that degenerative spondylotic change is led by age-related change in the nucleus pulposus of the disc. With age there is gradual narrowing of the disc space coincident with changes in disc proteoglycan composition. Later, cracks develop in the disc, and deposits of gas and calcification may form. Eventually the disc material becomes desiccated and friable. Age-related changes also occur in the annulus fibrosus, which becomes more fibrotic and less elastic. Fissures develop, and calcium is deposited. As the disc shrinks and the intervertebral disc space narrows, the annulus tends to buckle out.",
"   </p>",
"   <p>",
"    Accompanying this disc degeneration are changes at the vertebral body endplates adjacent to the disc. The marrow undergoes fibrovascular change or fatty marrow replacement. Finally, endplate sclerosis develops. Osteophyte formation occurs at the margins of the vertebral bodies. What triggers osteophyte formation is unclear, although spinal movement at ligamentous attachment sites and loss of buffering tissues between bony surfaces likely play roles. Osteophyte production appears to slow as advancing spondylosis leads to decreasing spinal movement.",
"   </p>",
"   <p>",
"    Uncovertebral joints are not true joints, but they may represent a slit in the intervertebral disc at the point where the uncinate process makes contact with the disc and vertebral body above. As disc substance decreases, there is more contact between the uncinate process and adjacent bone, leading to osteophyte formation. Dorsal protrusion of these osteophytes narrows the adjacent neural foramen.",
"   </p>",
"   <p>",
"    Facet joint degeneration may not be directly related to spondylotic changes, but often coexists. Disc degeneration is likely to put additional weight-bearing strains on facet joints, which are not weight-bearing structures. With unnatural movement of the spine, the synovial joint bears more structural burden, degenerates, and develops osteophytes. These osteophytes grow into the posterior aspect of the neural foramen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77488 \" href=\"UTD.htm?4/18/4389\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Disc protrusion and level of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between disc disease and lumbosacral radiculopathy was first identified in 1934 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/12\">",
"     12",
"    </a>",
"    ]. Disc protrusion can give rise to different anatomic levels of nerve root compression depending on the orientation of spinal nerve roots as they exit from the spinal cord. As noted earlier, all lumbar and sacral spinal nerve roots are constituted at the T12-L1 vertebral level, where the spinal cord ends as the conus medullaris. The roots then course down the canal as the cauda equina, until they exit at their respective neural foramina.",
"   </p>",
"   <p>",
"    Depending upon the nature and location of intraspinal compression, roots may be injured at any disc level, from the L1-2 level to the level of their exit into their neural foramina. For example, the L5 root can be compressed by a central disc protrusion at the L2-3 or L3-4 level, a lateral disc protrusion at the L4-5 level (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81881 \" href=\"UTD.htm?18/27/18869\">",
"     image 2",
"    </a>",
"    ), or disc protrusion into the foramen at the L5-S1 level (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79837 \" href=\"UTD.htm?16/51/17201\">",
"     image 3",
"    </a>",
"    ). Because of the presence of multiple spinal nerve roots in the cauda equina, there is increased likelihood of multiple, bilateral simultaneous nerve root compressions.",
"   </p>",
"   <p>",
"    Nerve root injury may be complete or only partial and thus may involve all or only a subset of root fibers. With partial injury, incomplete myotomal involvement may result, making the distinction between a radiculopathy and a peripheral nerve injury more challenging.",
"   </p>",
"   <p>",
"    The lumbosacral spine is susceptible to disc herniations because of its mobility from flexion, extension, and torsion. Seventy-five percent of flexion and extension occurs at the lumbosacral joint [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/13\">",
"     13",
"    </a>",
"    ]. This level, on the other hand, has limited torsion. Twenty percent of flexion and extension occurs at L4-L5. The remaining 5 percent occurs between L1 and L3 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/13\">",
"     13",
"    </a>",
"    ]. As the L4-L5 and L5-S1 levels are most susceptible to injuries from routine movements of the spine, about 90 to 95 percent of compressive radiculopathies occur at these levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/14\">",
"     14",
"    </a>",
"    ]. The incidence of radiculopathies is split somewhat evenly between L4-L5 and L5-S1, as the lack of torsion at L5-S1 helps to increase its stability despite its higher degree of flexion and extension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/15\">",
"     15",
"    </a>",
"    ]. Next in frequency is L4. Other levels are uncommon.",
"   </p>",
"   <p>",
"    Far lateral herniations are seen more often at the L2-4 levels. They may affect the rostral root. This is rare, as only 10 percent of far lateral herniations will result in nerve root compression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/5\">",
"     5",
"    </a>",
"    ]. Pain from the far lateral disc herniations may be more severe due to compression of the dorsal root ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other skeletal causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital abnormalities of the bony spinal column or its contents occur in 25 to 50 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/17\">",
"     17",
"    </a>",
"    ]. Congenital narrowing of the canal is not uncommon as a substrate upon which spondylosis may result in neurologic disease; this is especially true of younger adults. Other developmental abnormalities include tethered cord or diastematomyelia and spina bifida. They may lead to radicular dysfunction due to injuries resulting from traction of the root.",
"   </p>",
"   <p>",
"    Root avulsion is a rare cause of lumbosacral radiculopathy that may occur with fractures of the sacroiliac joint or with diastasis of the symphysis pubis or the pubic rami [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonskeletal causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection, inflammation, neoplasm, and vascular disease are less common causes of radiculopathy and polyradiculopathy (",
"    <a class=\"graphic graphic_table graphicRef57491 \" href=\"UTD.htm?3/9/3228\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Specific etiologies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes mellitus, a common cause of peripheral neuropathy and polyneuropathy",
"     </li>",
"     <li>",
"      Infectious diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Borrelia burgdorferi",
"     </li>",
"     <li>",
"      Cytomegalovirus",
"     </li>",
"     <li>",
"      Epidural abscess",
"     </li>",
"     <li>",
"      Epstein-Barr virus",
"     </li>",
"     <li>",
"      Herpes simplex virus",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV)",
"     </li>",
"     <li>",
"      Mycobacterium",
"     </li>",
"     <li>",
"      Mycoplasma",
"     </li>",
"     <li>",
"      Syphilis",
"     </li>",
"     <li>",
"      Varicella zoster virus (Herpes zoster or shingles)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute inflammatory demyelinating polyradiculoneuropathy (AIDP; Guillain-Barr&eacute; syndrome)",
"     </li>",
"     <li>",
"      Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)",
"     </li>",
"     <li>",
"      Arachnoiditis related to postsurgical changes",
"     </li>",
"     <li>",
"      Chemical radiculitis",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mass lesion or malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Metastasis (most common)",
"     </li>",
"     <li>",
"      Epidural abscess",
"     </li>",
"     <li>",
"      Intradural tumor, particularly meningioma, neurofibroma, and ependymoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphoma",
"     </li>",
"     <li>",
"      Myeloma",
"     </li>",
"     <li>",
"      Root sleeve cyst, such as a Tarlov or perineural cyst (though most are asymptomatic and found incidentally on MRI) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/23-26\">",
"       23-26",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arteriovenous malformation",
"     </li>",
"     <li>",
"      Vasculitis (nerve root infarction)",
"     </li>",
"     <li>",
"      Radiation-induced vascular occlusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is generally complete involvement of the root with radiculitis caused by leptomeningeal carcinomatosis, cytomegalovirus, or herpes zoster.",
"   </p>",
"   <p>",
"    With leptomeningeal carcinomatosis, the source may be metastases from breast cancer, lung cancer and melanoma, non-Hodgkin lymphoma, or leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/21\">",
"     21",
"    </a>",
"    ]. Nerve roots may be encased by tumor cells causing compression and ischemia.",
"   </p>",
"   <p>",
"    Cytomegalovirus radiculitis occurs in immunosuppressed patients with very low CD4 counts. It is characterized by severe paresthesia, and sensory loss and weakness. Both small and large nerve fibers are involved. There may also be bowel and bladder dysfunction from diminished sphincter tone. Cerebrospinal fluid analysis may reveal increased protein, decreased glucose, and a polymorphonuclear pleocytosis. Polymerase chain reaction may be positive for cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpes zoster colonizes the dorsal root ganglion and may remain latent for years. Reactivation is associated with a hemorrhagic lymphocytic infiltration of the ventral roots. Patients present with an erythematous vesicular maculopapular rash in the dermatome of the affected root that lasts for three to five days. Sensory changes characterized by marked allodynia often follow [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Root infarction may occur from either large vessel or small vessel disease. It is most commonly seen in diabetics where the microvasculature is affected. Such a process may be one of the causes of the clinical syndrome known as diabetic amyotrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/28\">",
"     28",
"    </a>",
"    ]. Diabetic amyotrophy involves the L2, L3, and L4 roots and presents with weakness, pain, and dysesthesia primarily in the proximal leg that evolves over days to weeks. This condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and classification of diabetic neuropathy\", section on 'Diabetic amyotrophy (lumbar polyradiculopathy)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiculopathy may also arise in the absence of obvious compression, leading to the hypothesis that the injury may be due to a chemical radiculitis, perhaps caused by the rupture of the annulus fibrosus with subsequent release of inflammatory mediators tracking along the nerve root sheath [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Electromyography may be abnormal even though compression is not observed on imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9619462\">",
"    <span class=\"h2\">",
"     Fiber size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like most peripheral nerves, lumbosacral nerve roots are composed of both large and small fibers. Different fiber types play different roles by virtue of the information they carry. Injury to these fibers may result in focal demyelination as seen initially with compression, or axonal damage as seen with infarction or more severe compressive injury.",
"   </p>",
"   <p>",
"    Large fibers carry motor efferent and sensory information involved with vibratory sense and conscious and unconscious proprioception. The typical clinical findings of large fiber involvement in radiculopathies are weakness and reflex abnormalities. Deep tendon reflexes may be diminished or lost. Clinical testing for proprioception and vibratory sense tends to extend across different dermatomes and thus is often not as helpful in the evaluation of lumbosacral radiculopathies as small fiber modalities, as discussed below.",
"   </p>",
"   <p>",
"    The smaller myelinated A-delta fibers and unmyelinated C fibers carry pain and temperature information. A-delta fibers transmit cold sensation, while C fibers subserve warm sensation. Isolated injury to these fibers is not common in lumbosacral radiculopathies. However, their dermatomal distributions tend to be more specific than those of the large fibers, increasing their importance in the clinical evaluation of radiculopathies.",
"   </p>",
"   <p>",
"    In addition, dysfunction of A-delta and C fibers even in the absence of overt nerve root compression may play a significant role in the symptomatology of radiculopathies. A study of warm and cold sensory thresholds in 32 patients with unilateral L5 or S1 radiculopathy and disc herniation found that warm thresholds (C fiber function) were impaired to a greater extent than cold thresholds (A-delta fibers) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/32\">",
"     32",
"    </a>",
"    ]. Since it is thought that unmyelinated axons, such as C fibers, are less affected by compression than myelinated ones, this finding suggests that the generation of lumbar radicular pain is mediated by inflammation more than by nerve root compression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central pain sensitization may result from nerve root compression. Supporting evidence comes from a small study of patients with L5 or S1 radiculopathy that demonstrated a lowered pain threshold in the contralateral root, perhaps mediated by pre- and postsynaptic modulation of opioidergic interneurons [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbosacral radiculopathy is one of the most common problems seen in neurologic consultation. Although data are limited, the estimated lifetime prevalence is approximately 3 to 5 percent for adults, with equal rates among men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentations of lumbosacral radiculopathy vary according the level of nerve root or roots involved. The most frequent are the L5 and S1 radiculopathies. All lumbosacral nerve roots exit the spinal canal at the neural foramina below their respective vertebrae. As an example, the L5 nerve roots exit via the neural foramina at the",
"    <span class=\"nowrap\">",
"     L5/S1",
"    </span>",
"    disc space level. Thus, posterolateral disc herniation of the",
"    <span class=\"nowrap\">",
"     L4/L5",
"    </span>",
"    disc usually compresses the L5 nerve root, while posterolateral disc herniation of the",
"    <span class=\"nowrap\">",
"     L5/S1",
"    </span>",
"    disc typically compresses the S1 nerve root.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     L1 radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar disc herniation at the L1 level is rare, and thus L1 radiculopathy is uncommon. Symptoms on presentation generally involve pain, paresthesia, and sensory loss in the inguinal region [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/1\">",
"     1",
"    </a>",
"    ]. Rarely, minor hip flexion weakness is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     L2/L3/L4 radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is marked overlap of the L2, L3, and L4 innervation of the anterior thigh muscles, making it difficult to differentiate these spinal nerve root levels based on symptoms, neurologic examination, or electrodiagnostic testing. Thus, these radiculopathies are generally considered as a group. These nerve roots are most commonly involved in older patients with symptoms of spinal stenosis.",
"   </p>",
"   <p>",
"    Acute back pain is the most common presenting complaint, often radiating around the anterior aspect of the leg down into the knee and occasionally down the medial aspect of the lower leg as far as the arch of the foot. On examination, there may be weakness of hip flexion, knee extension, and hip adduction. Higher lesions may result in greater weakness of the hip flexors. Sensation may be reduced over the anterior thigh down to the medial aspect of the lower leg. A reduced knee reflex is common in the presence of moderate weakness.",
"   </p>",
"   <p>",
"    Electromyography and nerve conduction studies may reveal abnormalities confined to muscles of the affected root(s), including the quadriceps, leg adductors, and iliopsoas, with associated paraspinal abnormalities. Saphenous sensory response remains normal even if sensory loss is prominent in the distal leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     L5 radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;L5 radiculopathy is the most common radiculopathy affecting the lumbosacral spine. It often presents with back pain that radiates down the lateral aspect of the leg into the foot. On examination, strength can be reduced in foot dorsiflexion, toe extension, foot inversion, and foot eversion. Weakness of leg abduction may also be evident in severe cases due to involvement of gluteus minimus and medius. Atrophy may be present in the extensor digitorum brevis muscle of the foot and the tibialis anterior muscle of the lower leg. In severe cases, there may be \"tibial ridging\", a condition in which the normal convexity of the anterior compartment of the leg is lost because of atrophy, leaving a prominent sharp contour of the medial aspect of the tibial bone.",
"   </p>",
"   <p>",
"    Sensory loss is confined to the lateral aspect of the lower leg and dorsum of the foot, but may be obvious only when testing sharp sensation in the web space between the first and second digits. Reflexes are generally normal, although the internal hamstring reflex may be diminished on the symptomatic side.",
"   </p>",
"   <p>",
"    Electromyography and nerve conduction studies typically show abnormalities in the L5 muscles, including the gluteus medius and minimus, tensor fascia lata, tibialis anterior, tibialis posterior, short head of the biceps femoris, and the L5 paraspinals. Sensory studies (sural and superficial peroneal responses) are normal since the lesion is almost always proximal to the dorsal root ganglion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     S1 radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In S1 radiculopathy, pain radiates down the posterior aspect of the leg into the foot from the back. On examination, weakness of plantar flexion (gastrocnemius muscle) is specific. There may also be weakness of leg extension (gluteus maximus) and toe flexion. Sensation is generally reduced on the posterior aspect of the leg and the lateral edge of the foot. Ankle reflex loss is typical.",
"   </p>",
"   <p>",
"    Electromyography and nerve conduction studies reveal abnormalities in S1 innervated muscles, including the gluteus maximus, long head of the biceps femoris, gastrocnemius and soleus muscles, and the S1 paraspinals, with intact sensory responses (sural generally tested). Soleus H reflex testing also can be performed bilaterally to identify amplitude loss or latency prolongation on the affected side. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link&amp;anchor=H4#H4\">",
"     \"Nerve conduction studies: Late responses\", section on 'H reflex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     S2/S3/S4 radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural radiculopathies at these lower levels are less common than other lumbosacral radiculopathies, but may be caused by a large central disc compressing the nerve roots intrathecally at a higher level (eg, L5). Patients can present with sacral or buttock pain that radiates down the posterior aspect of the leg or into the perineum. Weakness may be minimal, with urinary and fecal incontinence as well as sexual dysfunction.",
"   </p>",
"   <p>",
"    The utility of electromyography and nerve conduction studies of the legs for the evaluation of S2, S3, and S4 radiculopathy is limited. However, electromyographic investigation of the low paraspinal muscles may be helpful. In addition, abnormalities may be identified in gluteus maximus and gastrocnemius. Sensory studies are normal. Prolongations in latency when performing electrical bulbocavernosus reflex testing may indicate a lesion in the region, although this is not specific for radiculopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lumbosacral radiculopathy can be separated into three general categories from least to most severe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pure",
"      <span class=\"nowrap\">",
"       sensory/painful",
"      </span>",
"      radicular pattern, characterized by radicular pain and a segmental pattern of sensory dysfunction but no other neurologic deficits",
"     </li>",
"     <li>",
"      Mild motor deficit pattern, characterized by radicular pain, sensory dysfunction, and mild nonprogressive segmental motor weakness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reflex change",
"     </li>",
"     <li>",
"      Marked motor deficit pattern, characterized by radicular pain and sensory dysfunction with severe or worsening motor deficits",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a lumbosacral radiculopathy is clinical, and can usually be made based upon compatible symptoms and examination findings.",
"   </p>",
"   <p>",
"    Disc herniation and foraminal stenosis due to spondylotic degeneration are the most common etiologies for lumbosacral radiculopathy, and clinical symptoms are self-limited in most cases. Thus, immediate diagnostic testing is not necessary for patients with suspected radiculopathy who are neurologically intact and at low risk for neoplastic, infectious, or inflammatory etiologies. Nevertheless, testing is suggested to confirm the diagnosis and etiology for patients who have persistent symptoms that are not adequately controlled with conservative therapy and who are candidates for invasive treatment options.",
"   </p>",
"   <p>",
"    We recommend urgent neuroimaging in the initial assessment - followed by electromyography if imaging is negative or equivocal - for patients with any of the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute radiculopathy with rapidly progressive neurologic deficits",
"     </li>",
"     <li>",
"      Radiculopathy with urinary retention, saddle anesthesia, or bilateral neurologic symptoms or signs",
"     </li>",
"     <li>",
"      Suspected neoplasm",
"     </li>",
"     <li>",
"      Suspected epidural abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, we recommend a lumbar puncture and cerebrospinal fluid analysis for patients with a suspected inflammatory or infectious cause of lumbosacral radiculopathy.",
"   </p>",
"   <p>",
"    The most useful modalities in the evaluation of lumbosacral radiculopathy are MRI, CT, electromyography (EMG) and nerve conduction studies (NCS). A MRI scan of the lumbosacral spine will identify most pathologic states that may benefit from surgical intervention. CT or MRI myelography can assess the anatomy of the root sleeve. The sensitivities of CT and MRI are similar for compressive radiculopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/34\">",
"     34",
"    </a>",
"    ]. EMG and NCS have a high diagnostic accuracy for radiculopathy when neurologic weakness is present for at least three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and sensory symptoms such as paresthesia, dysesthesia, hyperesthesia, or anaesthesia that involve a specific lumbosacral dermatome are suggestive of a radicular process. Paresthesia occurs in 63 to 72 percent of cases, radiating pain in about 35 percent, and numbness in approximately 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, weakness confined to the muscles in a particular lumbosacral myotome should raise suspicion for radiculopathy, though few people spontaneously report such specific complaints. Inability to get up from a chair suggests iliopsoas or quadriceps weakness, while buckling of the knee is consistent with quadriceps weakness, and dragging of the toe points to tibialis anterior weakness.",
"   </p>",
"   <p>",
"    Elucidation of triggering and alleviating factors may also be helpful. Radicular pain that worsens with Valsalva or improves while lying down suggests a compressive etiology. Conversely, radicular pain that worsens with lying down suggests an inflammatory or neoplastic etiology. However, such symptoms have not been shown to be sensitive or specific for these conditions.",
"   </p>",
"   <p>",
"    The acute onset of symptoms with bending, lifting, or trauma may herald a radiculopathy. However, none of these factors is specific for radiculopathy.",
"    <span class=\"nowrap\">",
"     Bowel/bladder",
"    </span>",
"    symptoms, particularly new urinary incontinence, suggest a cauda equina syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for lumbosacral radiculopathy requires a careful neurologic examination. A summary of findings for specific nerve root levels of involvement is found in the Table (",
"    <a class=\"graphic graphic_table graphicRef75645 \" href=\"UTD.htm?7/31/7676\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional procedures (eg, straight leg raising, reverse straight leg raising) may be useful but their specificity, sensitivity, and reproducibility are variably limited. Vertebral tenderness is suggestive of infection but is not specific enough to be clinically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/14\">",
"     14",
"    </a>",
"    ]. The spine should be evaluated for any cutaneous abnormalities, such as tufts of hair, nevi, or pores that may be suggestive of a neural tube developmental abnormality.",
"   </p>",
"   <p>",
"    Deep tendon reflexes should be assessed at both the quadriceps",
"    <span class=\"nowrap\">",
"     (L2/L3/L4)",
"    </span>",
"    and Achilles (S1). Unfortunately, there is no reliable reflex to assess L5, the most common root compressed in mechanical lumbosacral radicular disease. An experienced clinician may try to elicit an L5-mediated deep tendon reflex by tapping the tendon of the tibialis posterior adjacent to the medial malleolus, or the tendon of the internal hamstring, which is served by the peroneal division of the biceps femoris muscle (lateral). However, the specificity of these tests and their reliability is low. Side to side comparisons are sometimes useful.",
"   </p>",
"   <p>",
"    The sensory examination is more subjective than other parts of the neurologic examination and is further confounded by dermatomal overlap and variability. However, it can provide important information for localization. Thus, we suggest testing the relevant lumbosacral dermatomes for light touch, pain, and temperature. Vibratory sensation and proprioception are usually not useful for evaluating radiculopathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific maneuvers can be helpful in determining whether symptoms are radicular in nature. These include the straight leg raise (Las&egrave;gue's sign), the contralateral straight leg raise, and the reverse straight leg raise (also referred to as femoral stretch).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The straight leg raise test is done with the patient supine. The examiner raises the patient's extended leg on the symptomatic side with the foot dorsiflexed, being careful that the patient is not actively \"helping\" in lifting the leg. Straight leg raising results in an increase in dural tension in the low lumbar and high sacral levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Las&egrave;gue's sign is the presence or worsening of radicular pain (not just low back pain or hamstring pain) with the straight leg maneuver (ie, hip flexion with the leg extended at the knee). In contrast, radicular pain is absent or unchanged when the hip is flexed with the leg in flexion at the knee. A positive Las&egrave;gue's sign usually occurs when hip flexion is between 30 and 60 degrees, though positive tests can also occur at smaller and larger degrees of hip flexion.",
"     </li>",
"     <li>",
"      The bowstring sign refers to the relief of radicular pain when the knee is flexed during a positive straight leg raise.",
"      <br/>",
"      <br/>",
"      The straight leg raise test is more sensitive but less specific than the contralateral straight leg raise for the diagnosis of radiculopathy due to disc herniation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/37\">",
"       37",
"      </a>",
"      ]. It is most helpful in the evaluation of radiculopathy at the L5 and S1 levels. In a prospective study of 100 patients, Las&egrave;gue's sign was positive in 83 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/38\">",
"       38",
"      </a>",
"      ]. One study of patients with acute low back pain found that the combination of radiating pain into the leg, sensory loss in the foot, and a positive straight leg raise test was predictive of a herniated disc with nerve root compression [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The contralateral (crossed) straight leg raise test refers to passive elevation of the unaffected leg by the examiner. The test is positive when lifting the unaffected leg reproduces radicular pain in the affected leg. It is relatively specific for radiculopathy due to disc herniation, but has poor sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/37,39\">",
"       37,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The reverse straight leg raise (femoral stretch) test is accomplished by placing the patient prone on the table and passively extending the hip and leg straight up off the plane of the table. This maneuver is most useful for evaluating the L2, L3, and L4 roots. However, the value of this test is limited by inadequate information on its sensitivity and specificity.",
"     </li>",
"     <li>",
"      Patrick's test is a maneuver where the hip is externally rotated with the ipsilateral knee flexed at 90 degrees and placed on the opposite knee. The test is positive if it elicits hip or buttock pain. A positive test raises suspicion for hip or sacroiliac disease. However, it is nonspecific for a radicular process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=see_link&amp;anchor=H25#H25\">",
"       \"Evaluation of the adult with hip pain\", section on 'Patrick (Fabere) test'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;For imaging of the lumbar spine, MRI, CT, and CT myelography (CT scan after intrathecal administration of contrast media) are equally sensitive for the diagnosis of disc herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/34\">",
"     34",
"    </a>",
"    ]. For routine initial assessment, an MRI is more informative than CT because it can also identify other intraspinal pathologies, including inflammatory, malignant, and vascular disorders. In addition, MRI is not associated with ionizing radiation and is less invasive than CT myelography.",
"   </p>",
"   <p>",
"    However, there is a high prevalence of abnormal neuroimaging findings in asymptomatic individuals, including some who have what appears to be frank nerve root compression by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/40\">",
"     40",
"    </a>",
"    ]. As an example, one study of 98 people without back pain found MRI evidence of disc herniation in 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, lumbar spine abnormalities on MRI in asymptomatic patients do not appear to be predictive for the future development or duration of low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although rarely indicated, CT myelography can visualize spinal nerve roots and their trajectory though the neural foramina. It is useful for patients with intolerance of or contraindications to MRI (eg, implanted electrical devices such as cardiac pacemakers or defibrillators) when standard CT fails to define the anatomic correlates of the clinical presentation. In addition, CT myelography is preferred for patients who have surgically placed spinal hardware that produces magnetic artifacts.",
"   </p>",
"   <p>",
"    A CT scan can assess osseous structures better than either plain radiography or MRI and is therefore helpful in assessing for bony disease. However, CT alone is unable to visualize nerve roots, so it is not helpful in the direct imaging of a radicular process.",
"   </p>",
"   <p>",
"    Plain radiographs of the lumbar spine are of limited value in the evaluation of lumbosacral radiculopathy. They can visualize bony structures but do not detect herniated discs. Thus, plain radiographs are not recommended in the work-up of lumbosacral radiculopathy unless there is a need to evaluate for infection, fracture, malignancy, spondylolisthesis, degenerative changes, disc space narrowing, or prior surgery. However, normal plain films do not exclude malignancy or infection in patients with a suspicious history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=see_link\">",
"     \"Diagnostic testing for low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Electrodiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary electrodiagnostic procedures for lumbosacral radiculopathy are electromyography (EMG) and nerve conduction studies (NCS). In combination, the information provided gives insights into the integrity of spinal nerve roots and their connection with the muscles they innervate. These tests are most commonly considered in patients with persistent disabling symptoms of radiculopathy in whom neuroimaging findings are not consistent with the clinical presentation.",
"   </p>",
"   <p>",
"    In a systematic review of evidence published through mid-2006, the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) assessed the utility of electrodiagnostic testing for patients with lumbosacral radiculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/43\">",
"     43",
"    </a>",
"    ]. The AANEM noted that the available data are limited by the lack of a universally accepted &ldquo;gold standard&rdquo; definition for the diagnosis of lumbosacral radiculopathy, thus preventing comparison of sensitivities and specificities reported by the included studies. With this caveat in mind, the AANEM concluded that the following tests probably aid the clinical diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral limb EMG",
"     </li>",
"     <li>",
"      H reflex in S1 radiculopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link&amp;anchor=H4#H4\">",
"       \"Nerve conduction studies: Late responses\", section on 'H reflex'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AANEM observed that the available evidence suggests a low sensitivity for peroneal and posterior tibial F waves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Nerve conduction studies and electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;NCS and EMG have a high diagnostic utility for radiculopathy when neurologic weakness is present for at least three weeks, which is why these studies are most often considered for those with persistent unexplained symptoms. The yield is lower in patients with only pain or sensory loss as the manifestation of radiculopathy. For patients with nonspecific spine pain, EMG can help to distinguish pain-related reduced muscular effort from true neurogenic weakness.",
"   </p>",
"   <p>",
"    In patients with weakness due to radiculopathy, NCS and EMG together can localize the specific spinal nerve root that is damaged, distinguish between old and new axon loss nerve damage, and provide indirect support for the presence of demyelinating conduction block at the root level [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. Finally, electrodiagnostic testing can identify conditions that mimic radiculopathy, such as mononeuropathies of the leg or lumbosacral plexopathy.",
"   </p>",
"   <p>",
"    From studies of the relative value of electrodiagnostic testing in the diagnosis of lumbosacral radiculopathy, the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EMG and imaging studies have a comparable diagnostic sensitivity, varying between 50 to 85 percent, depending on the patient population [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. In a retrospective comparison of 47 patients who had a clinical history suggestive of either cervical or lumbosacral radiculopathy, there was congruence between EMG and MRI findings in 60 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/45\">",
"       45",
"      </a>",
"      ]. Agreement between EMG and MRI was highest for patients with clearly abnormal examination findings consistent with radiculopathy.",
"     </li>",
"     <li>",
"      MRI and EMG provide unique anatomic and physiologic information, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/45,48\">",
"       45,48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, these tests have overlapping diagnostic sensitivity but provide different kinds of information. When precision is needed to decide whether the neuroimaging findings are etiologically related to specific neurologic deficits, EMG is useful to support or refute this relationship. In particular, EMG may provide objective evidence of denervation when there is no motor deficit or uncertain motor deficit. In addition, EMG findings may help determine the timing of the denervation (eg, distant past versus ongoing). This is particularly useful in patients with past surgery and residual pain.",
"   </p>",
"   <p>",
"    In acute radiculopathy (ie, the first three weeks), EMG and NCS provide limited but potentially important information. The needle EMG examination is more sensitive and provides better localizing information than NCS, but is not likely to show prominent features of acute axon loss until three or more weeks after symptom onset. This is due to a two to three week delay in the development of fibrillation potentials after acute motor axon loss. In the face of marked weakness from acute radiculopathy, NCS can show loss of amplitude of compound muscle action potentials by day eight after injury.",
"   </p>",
"   <p>",
"    NCS are carried out by applying an electrical stimulus to the skin overlying a nerve trunk, followed by the recording of the generated electrical response over either the nerve trunk or muscle innervated by it, at some distance from the stimulation. EMG records the electrical potentials generated in a muscle belly through a needle electrode inserted in the muscle. Both methods are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Somatosensory evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatosensory evoked potentials (SEPs) are performed by repetitively stimulating the tibial nerve at the ankle and recording the propagated sensory potentials as they ascend up the leg, into the cauda equina, through central sensory pathways in the spinal cord and brain, and then to the sensory cortex. However, the available evidence is conflicting regarding the ability of SEPs to localize specific nerve root compression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. As noted above, a systematic review found insufficient evidence to reach a conclusion about the utility of",
"    <span class=\"nowrap\">",
"     dermatomal/segmental",
"    </span>",
"    SEPs of the L5 or S1 dermatomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, the clinical value of SEPs for the diagnosis of lumbosacral radiculopathy is uncertain and they are not part of the routine evaluation of radiculopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lumbar puncture for cerebrospinal fluid (CSF) evaluation is indicated if there is suspicion for a neoplastic or infectious cause for radiculopathy. In the presence of a known primary tumor, evaluation of the CSF is usually indicated only if contrast-enhanced MRI is nondiagnostic. However, CSF sampling should be done in cases without a known primary cancer when neuroimaging is nondiagnostic, particularly in patients who fail to improve, have progressive neurologic deficits,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have involvement of multiple roots.",
"   </p>",
"   <p>",
"    CSF cytology can be diagnostic in patients with leptomeningeal carcinomatosis, but it may be negative in 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/22\">",
"     22",
"    </a>",
"    ]. In such patients, CSF testing should be repeated if there is clinical suspicion for cancer. Other abnormalities in the CSF include a monocytic pleocytosis, decreased glucose, and increased protein.",
"   </p>",
"   <p>",
"    Radiculopathy may result from infectious causes, including Lyme disease, cytomegalovirus, and herpes zoster. CSF sampling will provide the diagnosis in the first two cases, and may be needed in the third when there is no characteristic rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Discography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discography is a controversial technique of uncertain utility that involves the injection of contrast under fluoroscopy into the nucleus of a disc thought to be the cause of a patient's low back pain. The test is considered positive if it demonstrates an annular disruption and reproduces the patient's usual low back pain symptoms. It is not helpful in the evaluation of lumbosacral radiculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic testing for low back pain\", section on 'Discography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of lumbosacral radiculopathy is a herniated disc, though the differential diagnosis includes nonradicular back pain, lumbar spinal stenosis, cauda equina syndrome, diabetic amyotrophy, lumbosacral plexopathy, and mononeuropathies of the leg, such as femoral, sciatic, peroneal, and tibial nerve lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Low back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low back pain is one of the most common symptoms causing patients to seek medical attention. Most patients with lumbosacral radiculopathy will also have symptoms of low back pain. However, the majority of cases of low back pain are not due to a primary neurologic cause. Disc disease proves to be the underlying etiology in &lt;5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/20/20810/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, a specific etiology cannot be reliably established for most patients with low back pain. Thus, while lumbosacral radiculopathy is one possible underlying etiology, it is not the most common.",
"   </p>",
"   <p>",
"    Since the treatment of radicular and nonradicular low back pain may differ, it is important to distinguish the two.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radicular low back pain is generally associated with pain that radiates down one or both legs. There may be associated nerve root dysfunction resulting in sensory loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weakness that may or may not be overtly symptomatic. If the appropriate roots are involved, there may also be a loss or diminution of reflexes.",
"     </li>",
"     <li>",
"      Nonradicular low back pain is not associated with other neurologic symptoms or signs. Symptoms are generally localized to the spine and paraspinal regions and may or may not radiate into the leg. However, some patients have pain that radiates from the lower back into the buttocks and upper leg in a manner that mimics radiculopathy even though it is not due to nerve root impingement. Pain may be caused by injury of non-neurologic structures such as muscles, tendons, ligaments, or fascia without affecting the roots.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lumbosacral radiculopathies are often misdiagnosed in cases of nonradicular low back pain. This confusion is reinforced by the use of nonspecific nomenclature such as the term \"sciatica.\" Sciatica is often applied to conditions involving low back pain with or without radiation into the leg regardless the cause. Because of its nonspecific use, the term sciatica should be avoided if possible when referring to radicular pain.",
"   </p>",
"   <p>",
"    Diagnostic testing for low back pain is often equivocal. In such cases the diagnosis is typically that of nonspecific low back pain. Lumbosacral MRI may reveal findings suggestive of root compression, though the patient may not have specific radicular signs or symptoms. Persistence of findings from remote root injury and intercurrent processes such as diabetic neuropathy may also be noted on EMG, confounding the evaluation for a more acute problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Spinal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar spinal stenosis is a common entity, often asymptomatic, that can be caused by a variety of congenital or acquired conditions. The most common etiology is degenerative spondylosis. The major manifestation is neurogenic claudication, a syndrome of bilateral, often asymmetric pain, sensory loss,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weakness affecting the legs. The symptoms are produced or exacerbated by walking or prolonged standing in an erect posture. These symptoms represent intermittent mechanical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemic disruption of lumbosacral nerve root function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a few patients with lumbar spinal stenosis, more fixed nerve root injury may occur, causing lumbosacral radiculopathy, and rarely cauda equina syndrome or conus medullaris syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Cauda equina syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cauda equina syndrome is caused by an intraspinal lesion caudal to the conus that injures two or more of the 18 nerve roots constituting the cauda equina within the lumbar spinal canal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H22#H22\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Cauda equina syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cauda equina syndrome is typically associated with marked neurologic disability. The clinical presentation is dominated by bilateral leg weakness in multiple root distributions (L3-S1), and may be associated with perineal sensory symptoms as well as bowel, bladder, and sexual dysfunction due to involvement of the S2-4 spinal nerve roots.",
"   </p>",
"   <p>",
"    Potential etiologies include developmental abnormalities such as neural tube defects, infectious or inflammatory conditions, or mass lesions such as tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cauda equina syndrome is a rare complication of lumbar spinal stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Diabetic amyotrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic amyotrophy involves the L2, L3, and L4 roots and presents with weakness, pain, and dysesthesia primarily in the proximal leg that evolves over days to weeks. This condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and classification of diabetic neuropathy\", section on 'Diabetic amyotrophy (lumbar polyradiculopathy)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=see_link\">",
"       \"Patient information: Herniated disc (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five movable lumbar vertebral bodies (L1 to L5) comprise the lumbar spine, and five developmentally fused vertebral levels (S1 to S5) make up the sacrum (",
"      <a class=\"graphic graphic_figure graphicRef66123 \" href=\"UTD.htm?29/5/29779\">",
"       figure 1",
"      </a>",
"      ). The entire region is commonly described as the lumbosacral spine. Directly beneath each lumbar and sacral vertebra there is a pair of neural foramina with the same number designation, such that the L1 neural foramina are located just below the L1 vertebral body. Through each neural foramen passes the same numbered spinal nerve root. On each side there are five lumbar, five sacral, and one coccygeal spinal nerve roots. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All lumbar and sacral spinal nerve roots originate at the T10 to L1 vertebral level, where the spinal cord ends as the conus medullaris. A dorsal (somatic sensory) root from the posterolateral aspect of the spinal cord and a ventral (somatic motor) root from the anterolateral aspect of the cord join in the spinal canal to form the spinal nerve root (",
"      <a class=\"graphic graphic_figure graphicRef66123 \" href=\"UTD.htm?29/5/29779\">",
"       figure 1",
"      </a>",
"      ). The roots then course down through the intraspinal canal, forming the cauda equina, until they exit at their respective neural (intervertebral) foramina. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common etiology of lumbosacral radiculopathy is nerve root compression caused by a disc herniation or spinal stenosis due to degenerative arthritis (spondylosis) affecting the spine. Congenital abnormalities of the bony spinal column or its contents include tethered cord or diastematomyelia and spina bifida. They may cause radiculopathy via traction of the root. Additional etiologies of lumbosacral radiculopathy include nonskeletal conditions such as infection, inflammation, neoplasm and vascular disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar radiculopathy most commonly involves either the L5 or S1 root.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      L1 radiculopathy is rare. Symptoms involve pain, paresthesia, and sensory loss in the inguinal region. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'L1 radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      L2, L3, and L4 radiculopathies are most often seen in older patients with spinal stenosis. They are generally considered as a group because of marked overlap of innervation of the anterior thigh muscles. Acute back pain is the most common presenting complaint, often radiating around the anterior aspect of the leg down into the knee. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'L2/L3/L4 radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      L5 radiculopathy is the most common radiculopathy affecting the lumbosacral spine. It often presents with back pain that radiates down the lateral aspect of the leg into the foot. On examination, strength can be reduced in foot dorsiflexion, toe extension, foot inversion, and foot eversion. Reflexes are generally normal. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'L5 radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In S1 radiculopathy, pain radiates down the posterior aspect of the leg into the foot from the back. On examination, strength may be reduced in leg extension (gluteus maximus) and plantar flexion. Sensation is generally reduced on the posterior aspect of the leg and the lateral foot. Ankle reflex loss is typical. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'S1 radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S2, S3,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      S4 radiculopathies due to structural etiologies are rare, but may be caused by a large central disc that compresses the nerve roots intrathecally at a higher level (eg, L5). Patients can present with sacral or buttock pain that radiates down the posterior aspect of the leg or into the perineum. Weakness may be minimal, with urinary and fecal incontinence as well as sexual dysfunction. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'S2/S3/S4 radiculopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of a lumbosacral radiculopathy is clinical, and can usually be made based upon compatible symptoms and examination findings. Evaluation requires a careful neurologic examination. Immediate diagnostic testing is not necessary for patients with suspected radiculopathy who are neurologically intact and not suspected of having underlying neoplasm, infection, or inflammation. Nevertheless, testing is suggested to confirm the diagnosis and etiology for patients who have persistent symptoms that are not adequately controlled with conservative therapy and for whom invasive treatment options are an option. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend neuroimaging as part of the initial evaluation for patients with any of the following conditions (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Neuroimaging'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute radiculopathy with rapidly progressive neurologic deficits",
"     </li>",
"     <li>",
"      Radiculopathy with urinary retention, saddle anesthesia, or bilateral neurologic symptoms or signs",
"     </li>",
"     <li>",
"      High suspicion for neoplasm or epidural abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with persistent or severe findings in whom the etiology is not confirmed on neuroimaging, we suggest electromyography and nerve conduction studies (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Electrodiagnosis'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      When there is suspicion for an inflammatory or infectious cause of lumbosacral radiculopathy, we recommend a lumbar puncture for cerebrospinal fluid analysis. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Cerebrospinal fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to a herniated disc, the differential diagnosis of lumbosacral radiculopathy includes lumbar spinal stenosis, cauda equina syndrome, diabetic amyotrophy, lumbosacral plexopathy, and mononeuropathies of the leg, such as femoral, sciatic, peroneal, and tibial nerve lesions. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/1\">",
"      Tarulli AW, Raynor EM. Lumbosacral radiculopathy. Neurol Clin 2007; 25:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/2\">",
"      Ranson, SW. The structure of the spinal ganglia and of the spinal nerves. J Comp Neurol 1912; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/3\">",
"      Hay MC. Anatomy of the lumbar spine. Med J Aust 1976; 1:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/4\">",
"      Hamanishi C, Tanaka S. Dorsal root ganglia in the lumbosacral region observed from the axial views of MRI. Spine (Phila Pa 1976) 1993; 18:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/5\">",
"      Kikuchi S, Sato K, Konno S, Hasue M. Anatomic and radiographic study of dorsal root ganglia. Spine (Phila Pa 1976) 1994; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/6\">",
"      Levin KH. Electrodiagnostic approach to the patient with suspected radiculopathy. Neurol Clin 2002; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/7\">",
"      Lee MW, McPhee RW, Stringer MD. An evidence-based approach to human dermatomes. Clin Anat 2008; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/8\">",
"      Tsao BE, Levin KH, Bodner RA. Comparison of surgical and electrodiagnostic findings in single root lumbosacral radiculopathies. Muscle Nerve 2003; 27:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/9\">",
"      Foerster, O. The dermatomes in man. Brain 1933; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/10\">",
"      Bogduk N. The anatomy of the lumbar intervertebral disc syndrome. Med J Aust 1976; 1:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/11\">",
"      Groen GJ, Baljet B, Drukker J. Nerves and nerve plexuses of the human vertebral column. Am J Anat 1990; 188:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/12\">",
"      Mixter, WJ, Barr, JS. Rupture of the intervertebral disc with involvement of the spinal cord. N Engl J Med 1934; 211:210.",
"     </a>",
"    </li>",
"    <li>",
"     Weinstein, PR. Anatomy of the lumbar spine. In: Lumbar Disc Disease, 2nd ed, Hardy, RW (Ed), Raven Press, New York 1993. p.5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/14\">",
"      Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001; 344:363.",
"     </a>",
"    </li>",
"    <li>",
"     Ljunggren, AE. Natural history and clinical role of the herniated disc. In: The lumbar spine, 2nd ed, vol 1, Wiesel, SW, Weinstein, JN, Herkowitz, H, et al (Eds), WB Saunders, Philadelphia 1996. p.473.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/16\">",
"      Maroon JC, Kopitnik TA, Schulhof LA, et al. Diagnosis and microsurgical approach to far-lateral disc herniation in the lumbar spine. J Neurosurg 1990; 72:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/17\">",
"      Keim HA, Kirkaldy-Willis WH. Low back pain. Clin Symp 1980; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/18\">",
"      Chin CH, Chew KC. Lumbosacral nerve root avulsion. Injury 1997; 28:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/19\">",
"      Love, JG. The differential diagnosis of intraspinal tumors and protruded intervertebral disks in their surgical treatment. J Neurosurg 1944; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/20\">",
"      Anders HJ, Goebel FD. Cytomegalovirus polyradiculopathy in patients with AIDS. Clin Infect Dis 1998; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/21\">",
"      Viali S, Hutchinson DO, Hawkins TE, et al. Presentation of intravascular lymphomatosis as lumbosacral polyradiculopathy. Muscle Nerve 2000; 23:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/22\">",
"      Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999; 25:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/23\">",
"      Paulsen RD, Call GA, Murtagh FR. Prevalence and percutaneous drainage of cysts of the sacral nerve root sheath (Tarlov cysts). AJNR Am J Neuroradiol 1994; 15:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/24\">",
"      Lucantoni C, Than KD, Wang AC, et al. Tarlov cysts: a controversial lesion of the sacral spine. Neurosurg Focus 2011; 31:E14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/25\">",
"      Acosta FL Jr, Quinones-Hinojosa A, Schmidt MH, Weinstein PR. Diagnosis and management of sacral Tarlov cysts. Case report and review of the literature. Neurosurg Focus 2003; 15:E15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/26\">",
"      Oaklander AL, Long DM, Larvie M, Davidson CJ. Case records of the Massachusetts General Hospital. Case 7-2013. A 77-year-old woman with long-standing unilateral thoracic pain and incontinence. N Engl J Med 2013; 368:853.",
"     </a>",
"    </li>",
"    <li>",
"     Chad, DA. Disorders of nerve roots and plexuses. In: Neurology in clinical practice, 4th ed, Bradley, WG, Daroff, RB, Fenichel, GM, et al (Eds), Elsevier, Philadelphia 2004. p.2267.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/28\">",
"      Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology 1999; 53:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/29\">",
"      Holmes JM, Sworn BR. Lumbo-sacral Root Pain. Br Med J 1946; 1:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/30\">",
"      Marshall LL, Trethewie ER, Curtain CC. Chemical radiculitis. A clinical, physiological and immunological study. Clin Orthop Relat Res 1977; :61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/31\">",
"      Slipman CW, Isaac Z, Lenrow DA, et al. Clinical evidence of chemical radiculopathy. Pain Physician 2002; 5:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/32\">",
"      Zwart JA, Sand T, Unsgaard G. Warm and cold sensory thresholds in patients with unilateral sciatica: C fibers are more severely affected than A-delta fibers. Acta Neurol Scand 1998; 97:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/33\">",
"      Strian F, Lautenbacher S, Karlbauer G, Galfe G. Disturbances of C-fibre-mediated sensibility in lumbosacral disc disease. J Neurol Neurosurg Psychiatry 1991; 54:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/34\">",
"      Bischoff RJ, Rodriguez RP, Gupta K, et al. A comparison of computed tomography-myelography, magnetic resonance imaging, and myelography in the diagnosis of herniated nucleus pulposus and spinal stenosis. J Spinal Disord 1993; 6:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/35\">",
"      Norlen, G. On the value of neurological symptoms in sciatica for localization of a lumbar disc herniation. Acta Chir Sand 1944; 95:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/36\">",
"      BROWN HA, PONT ME. DISEASE OF LUMBAR DISCS. TEN YEARS OF SURGICAL TREATMENT. J Neurosurg 1963; 20:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/37\">",
"      Vroomen PC, de Krom MC, Knottnerus JA. Diagnostic value of history and physical examination in patients suspected of sciatica due to disc herniation: a systematic review. J Neurol 1999; 246:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/38\">",
"      Weir BK. Prospective study of 100 lumbosacral discectomies. J Neurosurg 1979; 50:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/39\">",
"      Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA 1992; 268:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/40\">",
"      Boden SD, Davis DO, Dina TS, et al. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. J Bone Joint Surg Am 1990; 72:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/41\">",
"      Jensen MC, Brant-Zawadzki MN, Obuchowski N, et al. Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med 1994; 331:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/42\">",
"      Borenstein DG, O'Mara JW Jr, Boden SD, et al. The value of magnetic resonance imaging of the lumbar spine to predict low-back pain in asymptomatic subjects : a seven-year follow-up study. J Bone Joint Surg Am 2001; 83-A:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/43\">",
"      Cho SC, Ferrante MA, Levin KH, et al. Utility of electrodiagnostic testing in evaluating patients with lumbosacral radiculopathy: An evidence-based review. Muscle Nerve 2010; 42:276.",
"     </a>",
"    </li>",
"    <li>",
"     Levin, KH. Radiculopathy. In: Comprehensive Clinical Neurophysiology, Levin, KH, L&uuml;ders, HO (Eds), WB Saunders, New York 2000. p.627.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/45\">",
"      Nardin RA, Patel MR, Gudas TF, et al. Electromyography and magnetic resonance imaging in the evaluation of radiculopathy. Muscle Nerve 1999; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/46\">",
"      Kuruoglu R, Oh SJ, Thompson B. Clinical and electromyographic correlations of lumbosacral radiculopathy. Muscle Nerve 1994; 17:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/47\">",
"      Wilbourn AJ, Aminoff MJ. AAEM minimonograph 32: the electrodiagnostic examination in patients with radiculopathies. American Association of Electrodiagnostic Medicine. Muscle Nerve 1998; 21:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/48\">",
"      Albeck MJ, Taher G, Lauritzen M, Trojaborg W. Diagnostic value of electrophysiological tests in patients with sciatica. Acta Neurol Scand 2000; 101:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/49\">",
"      Katifi HA, Sedgwick EM. Evaluation of the dermatomal somatosensory evoked potential in the diagnosis of lumbo-sacral root compression. J Neurol Neurosurg Psychiatry 1987; 50:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/50\">",
"      Aminoff MJ, Goodin DS, Barbaro NM, et al. Dermatomal somatosensory evoked potentials in unilateral lumbosacral radiculopathy. Ann Neurol 1985; 17:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/51\">",
"      Dumitru D, Dreyfuss P. Dermatomal/segmental somatosensory evoked potential evaluation of L5/S1 unilateral/unilevel radiculopathies. Muscle Nerve 1996; 19:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/20/20810/abstract/52\">",
"      Bogduk N. The lumbar disc and low back pain. Neurosurg Clin N Am 1991; 2:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5262 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20810=[""].join("\n");
var outline_f20_20_20810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rami",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myotomes and dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sinuvertebral nerves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pain generators in the lumbosacral spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Degenerative changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Disc protrusion and level of injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other skeletal causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonskeletal causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9619462\">",
"      Fiber size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      L1 radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      L2/L3/L4 radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      L5 radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      S1 radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      S2/S3/S4 radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Maneuvers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Electrodiagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Nerve conduction studies and electromyography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Somatosensory evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Discography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Low back pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Spinal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Diabetic amyotrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5262\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5262|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/18/4389\" title=\"diagnostic image 1\">",
"      MRI osteophyte L3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/27/18869\" title=\"diagnostic image 2\">",
"      MRI lateral disc L5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/51/17201\" title=\"diagnostic image 3\">",
"      MRI foraminal disc L5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5262|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/5/29779\" title=\"figure 1\">",
"      Cross section of the lumbar spine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5262|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4605\" title=\"table 1\">",
"      Lumbosacral myotomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/4/9292\" title=\"table 2\">",
"      Back pain generating tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40987\" title=\"table 3\">",
"      Systemic disease spine pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/9/3228\" title=\"table 4\">",
"      Nonskeletal causes LS radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/31/7676\" title=\"table 5\">",
"      Lumbosacral radiculopathy symptoms signs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=related_link\">",
"      Acute lumbosacral radiculopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=related_link\">",
"      Diagnostic testing for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=related_link\">",
"      Nerve conduction studies: Late responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/62/41954?source=related_link\">",
"      Patient information: Herniated disc (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_20_20811="Signs and symptoms of spinal cord injury";
var content_f20_20_20811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms and signs of traumatic cervical spinal cord injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Altered mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal motor examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal sensory examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal or absent reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck pain at rest or with isometric neck motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased cervical range of motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior midline cervical tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle spasm of cervical muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower extremity symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension with bradycardia (neurogenic shock)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diaphragmatic breathing without retractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autonomic hyperreflexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia or hyperthermia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20811=[""].join("\n");
var outline_f20_20_20811=null;
var title_f20_20_20812="Host factors and meningitis";
var content_f20_20_20812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Host immune defects predisposing to meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Host problem",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism favored",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency of defect actually leading to infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Absence of opsonizing antibody",
"       </td>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Common in all age groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"       </td>",
"       <td>",
"        Common in very young children",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Asplenia: surgical or functional",
"       </td>",
"       <td>",
"        <em>",
"         S. pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Complement deficiency",
"       </td>",
"       <td>",
"        <em>",
"         N. meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Glucocorticoid excess",
"       </td>",
"       <td>",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Cryptococcus neoformans",
"        </em>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        HIV infection",
"       </td>",
"       <td>",
"        <em>",
"         C. neoformans",
"        </em>",
"       </td>",
"       <td>",
"        About 5 percent eventually get cryptococcal meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         S. pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Common presenting illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         L. monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bacteremia/endocarditis",
"       </td>",
"       <td>",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"        ; various gram-negative rods",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Basilar skull fracture",
"       </td>",
"       <td>",
"        <em>",
"         S. pneumoniae",
"        </em>",
"        ; other upper respiratory tract flora",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20812=[""].join("\n");
var outline_f20_20_20812=null;
var title_f20_20_20813="RV dilation and survival";
var content_f20_20_20813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right ventricular enlargement increases mortality in dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among patients with an idiopathic dilated cardiomyopathy and left ventricular dysfunction, survival was much lower in those who also had right ventricular enlargement (p = 0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Sun JP, James KB, Yang XS, et al. Am J Cardiol 1997; 80:1583.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20813=[""].join("\n");
var outline_f20_20_20813=null;
var title_f20_20_20814="QB QD and urea clearance during SLED";
var content_f20_20_20814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing determinants of urea clearance during sustained low efficiency dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 310px; background-image: url(data:image/gif;base64,R0lGODlhHwE2AfcAAP///w5VWlBWcD8otlQ2v38ZfZ8TXRFdLrmZjN3NxnFON7cmUVQAAAoZf9+qpXArl7wmIwhLl1A9Ht8CCHcCCC8FBQgOKAARV15GVICAgAAAAMDAwEBAQP8AAMwAAABmMwAz//8zAKCgoPDw8FBQUBAQEDAwMP+AgP/NwP9mQICzmeaAgP/AwCAgIMDZzXBwcNDQ0PLAwP+ZgECMZoCZ/2BgYODg4OygoMDN/9lAQP9AQEBm//8QEPD28xBwQLCwsP8wMBBA//Dz//+goP9AEP/z8CB5TaDGs//w8P9gYNDZ/zBZ/9Dj2ZCQkM8QEGCggP/Q0KCz///g4Pzw8DCDWf/Z0NYwMPbQ0P9ZMP+NcP9NIODs5v/AsCBN///m4FBz//8gIFCWc/+zoPng4P+AYN9gYLDA/3CN/+Dm/5Cm/5C8ptIgIHCpjbDQwGCA//9zUP+mkP9QUP+wsP9wcNxQUP+QkOmQkOJwcO8DD88JL++wsF8fnw8AAK8gYCZSKZ8AAFAwMMCgoD9G3x8s3++2s4CMv78AAFBT3x8AAO4jMN8WMJ8yf+8AAJ9Tn4CGnwBSf8DQ8uDj7495c79TZqCw7z9GIwBiP9/AwJ9fMlBvbL9NgL8QEBBD1cDG35CZv1CTf0CGgHCAv+9TYD8jMN9TJu/W05+mk++WkzA5329MvwAGH1Bw7+9QUGYzGd9GX2CMzJaWgz85coBGX59fbO/p44xmU7+mjKZZTYCT3xA53xxpPI8JL4CmzJwpHN/Txt9mgK+dz28Zf7CzwG8JL+zm4yBMvF8jkn8jWV8TX18zUl8sbH8TX++ToMZsZkBDUM+Zv8C5rRBsTBBpWb9zTQBGsihRf+Dp829GnwAfnx88nwAmvz8zjKCcj3BgYL+AgL+QkFBDQBAgYDA2UO9DE79gYK+Av69gn522o1B28sIWEwADDwAv0oCTeR8zxe92c1NfP01NgEBTn19Tn4I1I58gIJ8mP8+dlt+MhqBgYHmTeY9JFtJmYzVcNR9Cha9cj68DDyH5BAAAAAAALAAAAAAfATYBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cqV6AYYAzeIFTvwR4YmNrqqjQojgwYOAzXIlSvwhQYTJUqkXWuQLF+hHOTCFSh3LIARGkoAaKLhRdgMkDNs6EpCxN+hG97GfUticma4nx9D5pCBK+IRl4WGFkgiQ43ENkKvLgiZqwgSqVVrLhj4610APzTgNlh7a+XcQGEwNrFhxAYTrhOjbqHhBwkNlomX1noa+c/AczfY/zAh1wRYADDIl3B8sHjW2961usfqN/7V+fbzI8Wvv/9Q/lTV559UAE5lQnYDErjdVRu0kCBVBUbV2oNTRfiUDSWgRmFUFjpVQw0bKnjVCHqF2NQGkZF233AmLoXiaAtS1cJkLT7V4VIimFAjVDcqJeCOS/UI5JAhCUnkkRwZWdSPSB6lJFHHNanUk0J1J2VSVAYF35VYxvhUlFw66WVTVoZpVJY/bWnmmWMyBeaaRKHZU5lw/temUmrW+dOLGagIFZN67sSnn4EW6pCchoaJaE6AJsrToji96ahPkNpE56Q9VVpTnphmeqdRkna6k6YzXSqqTqTKxOmpqH4KJYIYIf9Rxwl1ICEQEizkCkVDUJxwwhC35qrrrUP8autDuR40hA7HJgSFDsBylSpMplIEBQ886NABD7uy0MG3HYCxq0LgdjAHAN6Cq4NAQHSgLRAQfXsQGOsuJMUJLHQ17UurVgRGB7tCES667qKLra1QCJurFAIBK3AHBAMxrBwdxAFAHB3IQRALJ8gRRxxInACtQPIW5G20xcqhwxxIJKHDrvfm+2sdOiTRbIWuqkYjRgLDyy7A3tabRAd1AKBtuScQJMXA3mabBMMndJB01EkPFDUP7WLNQwcMl0xQEjwMpC0Y/2bLtNQAfAvEv0lYta9SQYvdQa4FA0A1QxhrDEUSInf/AO/dd1s9d9rrRp2v17eaKzfBSWvLOOEAIFE3hDl3tXTYAm2Na91DAzuHDqCDHi0S2kZLkLx1KD4H0QQZDrnriAMwBMCLe9s4xLZDrvufKVbuU6MVrR4HCxif663EUftcrK++5itFuzr4em8cfa+7NBgs/Muw4IcXPvi3zLPrs0CO514+2nVP/tSgvvd0oERyaJzQCVujTfC3PNisULrgsiDHvxU71hD+BQbTCQR23jtcuQAgMAOe73aPS1+9KJeUBklECjyQn0IwVgcD4gRsN9PP21QyIYggAQjnYggUysaTDj5ohCjBkIYe4jJWEQQGYzkPSWB4kg9FZAg8CKGo/+wyl8HssH05IdFeHHKtfNmQMCWIDKxEwsOSZIBFDTlh1Z4IgBYgcSNVJMmMIPIxLg7kBRzIoUnCKJIcQaQOYBAiq8AjmDV+0SbAM4jAxmVGAIggMhmYYpHuWBQk8MCDfVQJG2NSs0QCgAMwQCMHJsmeIy5pZws5ARDkyCoNbICOu7EkUd7HEDlwy5EvWaRHLMgQDGoQlSNoghRFwj4o+Q6FqCQIdYpIy94NRYYMmcP4cgkA4ajRioSMiQ8XAsTtERMALwBRSlS5ESUupIkXEUIaaJAGIQhECDgIpxIaogQa0CAKA0HDNs0wECFE4ZzefEg4DxKFHcQzIUrYATphIv+CuYRyJNTUyBUXosWLKCEIQdgBCIIwThyA4KEg6MI4FQJREJwBAGhA6BIsKpCNKnQJEHnoQbqwA4aggQY4iEliJsmBSgI0mS8Zo0JqeJEugGCcSogoABxaUhwg1JtKCKdQ0SAQdOYUBAA4AwjSAIAggEAIZgDBFwDwBRCwcyA4oIEZvvAFIdBAnwIRaUEcus93mmEHZxCCG3YwzpOm9Jxp2IEb7nkSLyoSpi1xo0LgyMmH5BSkHb0pTwXihqUCQKEVpQFB0KBThabUsTQAgWIjq9iBRDYIG8WsU4kqVoK4IQgDUWgXbJpQnTpUsQ9dgk3doJIXeBEyggRJQDGSxz3/YmSwAnEsbinLkKqy07GHBUFWJQsA3lpWuAAAQUkjm9LOfpOjuUXqaYO7U+IqFwBCuG5KQGnElzIFCWAomkPMcFWDMBa0AnEqOLVbWHSeYQfwhe8+haDQffoWABtVQho4qlSmHre5y0WucwEQhZuGVrrEVWh1UVvS5DYYJTg8piiV0kiHHLS8BlHqF3BQ1Ys6dAnDBew7zWnOlKLBo+ZEQ4G/ENUuYDSiOLApUf/r4OIKWLLm7Chgo7tg6k5Xu9ql4J4wWRBN9rUgQlhCZRNCA6cSt7oPDcJcFeLQiqb0DE5dwkSjYNMu7JPG12VucisKgJx+2ccJRjCDw/rgkvyg/yWztQgpDcKCUzqEq3de6plx8lm68kQDXlziSeJMEVYaxJCIZPIS/IxP0vIkDXvmiXXkEioq4pWEdwJC28bLUDPaIAPUWY+gERLIgcCgBhyowXlGgEYSvLk9l45hhg4iTL8GAcNm3MBrPJkQEQRmMCSKYl5QE5gXkIfIAiG0RJZZEFM6cyFJXjIsm6BDgxh7N/0E0WtEYANA+1ED0gRALXlizYJc65ULwTMxRRDbgqzGLaWBt2xCOe5RYfFWQNgiQ2iw6GdOkiHv1kC8BT7v7g5E2RCR6dcmyBAzdNrfBj/IarINgG1320EU1w5P9EoQIB6ZIBd2JJ8g04KIF0QEr/8JdLAzMOxHNubYsObJj2zbkGij0i3+/OdBJDlJsJw61atu9as1HhTwirch6hY5IGFrR6GU0SH8ZvQzm64TAfHVIVF4ODE3QAKWutTSO5lznfm4kCZHGiI9UIMK1NADgfTABXBngkPevgW3wz3ubj+CCo7Q9ofA/SBHmEHfE8KEGRwhJiXwp8k/gnCAO+hWh6z5F7RsESb4wAcz+IAP5O6CD3j+A0aQu0JcEIYPqEAgnf/8DARChQ9kngoQ8fxBjLD6hWxBBS5A/NeRqZMSGm3TCzmxPS9ihA/InQmgB0DnV++Cy7edCXeHe90B8PnTK/8DVMB7Gz4QBgCUvg0EcYH/CtoQhjD0QAWGF4jsC9L5wwNA722YARt68IQZyP32ud+7GmbwhMGfxNcS5l04AUwAIEwft1NBcFEXgXywx3rGt3wC8QQfoAYAkHmfZ3oDoQIYeH2Y9wR1p4GnB4IEoYE+0Hol6AMfUHfrRxBP4AMDkXlGUHyYl3ydd3qeRwXF9wQqsWt1xHs4sUzOxhBpEARnhxBtAH4HAYECkXlw53oCIYIKAYVM8AToh30AIIJQ+IQfkHtOqIFc+AEF0QMfwAYvCIY1WIFmiIFOKIa1hxJ3MUs+aCklAgBAkGgEoVYSNXctiIQGsQWaNxAo+HZOCAASeHhsMAOIiIjud4UbSBCy/6cGYwgAbDCBI7iF1Ld6Xkh9YEgQR2B8ZXh9p5d5oHiJ6teGJ9FSd4UTA2Uw0LYE/dYQLmAE5qcQkxgGpBeJnZd9GtiAeqcCvoh7qCeBT5B/YVCFq+eHRhCLKViJXIiJluh5v8h6DbiEaRiK1UiK2IgSNVACXkd1NiFTfKMQB8VaDdEDbOADFMgQKoCCG5h6mtd/C3GBYNgGxcd9fXcExWcEi6iFzciIX/h5AIB8+yiKZ0iQalh7g4gS3NVLMHITerU0z1YQBVaEBsEEVDAD0+cQpacG+4gTLeh/3lFvNOEXJwB8BvFZE6WOlBgRTCCDPMGRLxRrJMEDToRkrih1Ff9JBVQgelPnjTcxBMM0EErQBVPGEGrgA9bXk4Mmkx1RH3VoEFnnX7Y3A6GnlNPElBwRJXWWYUGQUgxxBD4wf1YJAyIwQwIoE1YSju20A0swYwrRA2GQjFYpEJkRRWYpW1ipEVsCkUK5BF3FEG3gA7M4l3TZJ3mZEI1XEFFSkgORddKGEPTnA3xolWbxadUGdmipARpCkwKRURQ5ELE4mHNJRFwXbmfJT8MBlKGlgAlhjuhImANRAjXAHH3iky8RJU9ZXK+IEBaJkbAZF5+ka4vnEYkpEN2xlQiYkgehgen4mwLBASbQAtfRBLaZV8MRjkLQBVKZkzvpnDeUeHdxl4P/JBNkwZdJZxBHmZTeSRBfgRLF2TptkwZdIHVbQJU8uZ6soSMYcph94Us0QZMH5ZUFAZZiiZ8EUR11MZwZIZIs4RdAaXNhGJe5Z6AFgaDQpKBJwp8TgZtD8F4GAZaiSaEDQQLrYRfUGYcscZw84HBuKRCW15EiKhAwsEsmIJ54yS/X+Qu3FoZUoJ4x6m6XeZorcRxLIwis+YLd96MGAQNdR0nViRLdcQIGsJsCwQZUAJJK2kWK96T/Nxw8QADK+X4+kJFZGhf3hqIkZBlDkAfbGZA+MKFlShAksHsTphLdAQTmEIZG0JxxOhDb2I1oihLw8Qw84GdUoIN9yhtbGqgn/yEWStAH+kaIV5qoMYFwQnAIXMOJPoCliRpLcFinKnEGBWCSyHefLjEFdrACdjAFAjEFMfCqV+AQrjoGAzEGqaoHAzEFN7ACN8CqD/GqB3EDOeCrCXEFOXADMXEdvMSoJCEWDocHNdkDPgCjLHEFTuAEOeABThCrMeAB3uoBaxCrChEDdOABKyAQY3CtVuABdyAQ65qtVgAR3noQa5ADDDEGKxADKmUXn6ShpOavDHEgS9AI49MDhzoTa+ABsXoF4AoA3WqvMXCtrHoFr1qxtAoA33quAHAHHmAHAOAEHjAFeuABdAAA5YqrAxEDK6AHdEAHU7ACxyoQ81oQ3YqsAP+wq3qQA3cwBWWQA7GKr/rKq3aQA2VArCfhSXpRmyHBoCXRIAeVm5I6Ewwbr+6qsA8rEGXQsQCQrd9qrgOxAl67tR6gr9mqsl4LthorEGDrBOvKtiBLqzNLEGXgBAORrWuQsNjasN16rt5qBQlbBipRArfRAtzIkIaJaW6QCpgDAGpgBJzKERT7qnqwAvmKEFcrEGV7uWi7EJsrtmQ7tpvbuWo7thhrr2Crr3Hbquxatx7gsF6bra7Lt/Y6BR5grynBbjCQF0F6o7IWCUHgClXTfKY6Ebu6AnSQA8i7rt9ar8ibA5SrrwcxBto6ECDrqrWLtR6ArHfQvMhrswDQuSf/CwDregV2sLoc67FfS7rXe7oY27oEcQMKy7qxK7bze72lqxIwsLtCShIfEgWCkKlbMK0Wga9sS7k3ULHQOxEcSwfkurrdagVmS7XFS7mV67BZWwb6Cr90MLJrAADSuwYxkLAXO7qoa7rqa66U665Ui7mtu7f068L2a78KiaGMB7AIoURLsAhtY7BkSBExcMEJvBErALJh263e6gRFuxBd6753ALJWIK43kLBr4L0kfL/su8QAwLBUDLsuzMVeG8O2ixI/oCNX6Z4k4FOcGQamCBE3YAVOsAIj/BHlagdUjBNza7Q+sZDMChIz4gYPAC8qMKkQQcBWUMcgcQV4yxN0/zwUPIeKe+wROZJdijAEgTm84wrElPrITbkBaUAAYUMF1IoQbfzGcSyiIgCeOjeeKNEFkBqLDwG/6FumLUAdHCCbXAoSODAIXFOMDgG/hvyj1aEB0GSamNmsG+AGo+qHj1sQvkypngQdXXfLHWECjgAC0PoEiLoQzUypJlADOEenNdy0LUADewAE0kqmopy9mUwQTXCimqwRrdEFeTAE6McQ27zOlZkB+kucNjwQGEIJAxA2cqkQ95zJpEkCxNyU/ikSH/IFBnAC+KjN6rzOAiGbtEnDFsG0HUEinaDLUpB+CVHQ6+xJaYRq0pwRV0QDo9p8BD3RFP2c0TmdJ40RM//SBdfso+/r0i+NHuBZozNtETkSBeWszOn8yy/dnktJSxuwA/PMBtnMzDp91GMRgMUMEmgQ0OccrFH90jnXg6DqEWfw0Pt3ENZq1Ou8dEz3zhUhFqjANUYwma26BrG807SBGzbAAUO3vxthAvEwqhFtEFYAuHR9EIIrECat1hPRIDsArSAtt1aAx4NNGDSitF8NzwJQzs0HkjfgBJAd2QBgAibwAz+wHj8tERiyCvNMhTS7rZ59EMEhF3OIEc6xz29TAwLgyX5IpmXd2gjxaWgxETknEP1UHja6LySCCw+tAk89BVaQtrzNEXIRGRWtmSYacx1xRZhaCptHEDlQss//7RHR3QSoUXCicbgd0QKe4NemeAeP/d0ewY3U0QLOoRmzodFAbQJuAK1vPRCbXcruzRHHRt5EtxEbIAzlTI8DwbDi+hNFAAcyAAdFIBBFgAIUXgUMMeEUjgIWDgBe4OBcEBEUfhBZQAYMIQYpsOE2waSA+hCRtAGnrAFpkXispgHuTBD7kgbzDNLpatY4UQVEQAQpEAJEYOEoEAJGHgJagOIHUeRHngIc/uNYEAJZABFGbhBeEAIywBAoIANegBPksaws7k/ZMdzhad0c4cmW13bM3a5BoQUhYOFVgOQAUOROjgI/HuFVkOEU3uVFjgUVDgBZEAJwAABEEAIRPhBb/84Fb/AGRSADKSAGAlHlBSEDIdDlACAGMsAFKZAFRUAGJz7nXA4AMiAGcJACZHDoL4EdwuzNEuEczUEQs42Yh7kBhfDQT9DDxysUcY4FAxHleR4CTg4AZCDoABDkR47lcy7kpt7lQY4CxR4Czj4QlE4EUU7thd7lkk4QWvAGAxHkWuDmQC7nlO7sRo4Fbk7iMOFJM4JGpe0QJtAAHZAAy7gC7R0UdN7t0H7voo7sCFEFZODoIcDrzf7s0S4Q4w4AwL7v5B4CBcEFIfDhAhHkyZ7lEn/wCV8ECQ8TXrRrZ8q7C2oBo6rcN8vaNTHhXCADBV8QV04EA1HoE57xww7pWf+QAjRP85BOEFX+Bg8PAL5OEBbv5BbP8ARBBiyP7xP/7AqP8MGe8S+RvyNAAiRgo+EMzw2AB4TwptYaxBbBBVmA8hnuECYvAzMf5QG/6SlfEIH+Biig81Pe51se8AKB6TIw9ygv6m8A8E4uBiHwBg6vBZMO7Uqf9EZO9wCA8VNu9EVO8Qz/85Ee7DCRz/t83ViJIX8ceFPgBDwOEVlABGJf82Rv5DWfAnM/9uW+6ZmOAqjOEDJQ6PzO5EJ+6grBBW6+94e++QGv5IIP9IB/7AwPB5VOEBKf+EjP+IEPEwed0B5/ETUQDvNsBOcQ2BlRBViABZZ+EBiOAic/91yA+hn/ofNwcPMzoQWOfxQWjSIYjdJMSSLXwAOxWAYrbBFiwPkvUQXgThONfvZFQdLC2e4KARAZxBk4MUPBmikAFC5k2NChwiJkiKB4WNHiRYwZNW7k2NHjR5AZOZhoQUJDk5AfM2RIybCFvA4JDqS70hJAFS0pitjk2dPnT6BBYZTQoMHEiKAWV/IUYWJRkicSbtiEEwJOUqxZtW71uQEG14ZLbW4IhYfQBwgti7zRUgXsW7hxuXLgAHfDygwcWPJsBESF1JQoiLzZKdfwYcQg89rFq5cnmjxDfPRKCFIGETGJNW/m7PCFBrocXsAVG3LDhnI8jvhZAdJLCixuO8+mbZhD/9Gidd+WBklCRJ8TRuZV5uhFDJEshWsvZ968JW+PIzQA6wDtQOuNVbJgCZGCi3Pw4VvaOF1eLvSOIkhoSjKj1RiMRcRI1JLlu3j8+TlmwF30KOm9enMEDwcO2MeiKuBIoTs4ZNPvQQgrEiG0kTQYbbcAo9PAHyCigq8hLrLQgggyxFAuQhRTfOgF3cBCbyMRnFHkFB+aYYiLN0LAIgsHVfTxR4VYBDAkEmThQYVKaoJICzi8APJJFCcMzQQLh/xIugWCu4UhGVKA8ksI+evvPwxBEmGUDkzxI4aFvCCiRzDjdI688jY4L0OONqgnCSpqYegNMuQUdFCeXsxICB4QOP9gKoUEO5FQSCPFyFCMmAEiDAUYwuIqSTv11CFKKzotkXs+cGAhOLT4dFVJ71rJsY5IwIeHJ95ZqIiJWNV1UFfzwhMj6Vhxxwd7FsrijV2TJTRUh0QApAN2+KmsihCcVPZaMJltiAR6RDECgYVSkAFbcqHUdiHpGJFEl8q40OLRcuMN81eLRGAgkRlgWUiLzOT1N8JzFSLhj1kO+LDLfxN+MGDpJvgkH4XchFNhipkL2N5JPiBGITICrfjj5gIOxJBMnmiUCHhBVlmzgE9YwIcEFMJi3JVr5ixgHjCYQSExVLX558S03YCcPKJpAwBcKQJ66TszMuGPZIxQKAsvmbb/usyLNkAEjwCOAMCLaq8WeytmSaDgGB96AEDcsdv+qVdYK7KBD0YCUAEALlB2e++xGqN3oRoYMMCSLQDgl2/EC/0bgBFKmCAWkxFOfPKQKM2AgTwCYCJpyjv3iNIWDFFm5449N30jQ0WoAI9H2nD0dNgvMnQDCAqQmu3Ycwf1byk66OeInnUXniFDTzBAGlqIuG944V/cYJNt2JCc+ebpNWGYR3wJm/rqHdLamCdSyIL74dEzOwJb9CZfd+jmDgaUw9dnH8/As8EEC/m7R7eEZarJNX/TwS1DlxuAPjwGQM8J0CW7iMA4rIVA2JVGdXtQAM0gGMEAfeMf1CDFBXNX/5okFAADy/Og6cTSu3ZMo4SxE4s3kNGPia1wcmKpADa4IUMMAiAQqihGynCIuKUAogG8+OHpVnIJdXBCbUX03EpqcIFXMNGE3eDDOqwhRabZoAkZ+IHsSnABdGBxaTYoQQmodKGHZIAP2oCEGIH2GZQQBSkLgZsFcoEXPOZRj3vkYx/9+EdABlKQfrSTFG9jp0MypFfggEchBilIujxykJGUJCApKchCMjGRiUzj4lISsM95snKidCNDTNJFKn2lk0kBZUdaiTpSllIhItAACX6ggRYoJZahxMorNeJLLL6AKCZQ5UNOk5RjIjOTb1umLJ35TGhGU5o/GoEIMiCCOf+Op042UAgMVlJMj3gFXdbE5kJ+kIEmcDNPxaxTJs+ZzmlehEq3MUGh+sOSW7agBRroYke8CZqFzNMoQTJKGdWJkX+2qD8aIKgJDBrPh9ySBAA4pU34U4PTcDOVMBhoR24DUABIlKL8lE4JANCEKokkNwspinlKetKUQpR4GmAJf3apFFzqBSlFUQhPwwlSmwLAphsAKFFbhBGjshQ0JLBTUpMq05nWlKY2EcELMrDP0fjUpx15alCHWlSQZuSpFM1ADTRQAvKA9ahQRelo4NgVgMrxpT/VTVsBAEeO1lOkGhnrQg6Z15DWEqoMsQEuN7DPgxKpBledqllXooEaeAT/Big1wQZGUNgWHFYD3NznD0wiAo1M1iiW3YAJynpWpHT2s4NliAj22QLQWpQoJbjQCExSy2xu5KMtBYBrcRlbGFCJtrrtzwZsQCWjqDK4Z0Uja537XOhGV7rTpW51rXtd7GZXu9sllw1WElsA0EmcIBnBeBvCAZRgREjclQstW0Cl/4ipKBP9SF9nqYFmPsSa7I0LZpGC0sjaVDoMlRAXRTOCGnDgK/YFAAdyqZBr5kUEMCABCZCyX+/+gEU35W9H7Mq4swoVNJ9Z3G30eVYTA8C+hU0vAPxDlPdCtsEMJSpoiALeDvskqD1lKH9aYOLEMuQ2Kp7qkO37mWwClD92rQKokad6Sw7nOCO0pC9gvTrVhziZJU5ea0kYomT8urguWiZylKWMESpxkUpdvGhpNQDaEqyVzE5uwXcD28+e1mXJYp5xmf18Zp8guCgl6Kd8S8ASjuK4z0TdMo37UxcSPJileg5zkx3NEkYDOihl/AGeG9IESYOksGbWNFdEQBT6gsrTH/FmkEv9aljHWtazpnWtbX1rXOda17vmda99/WtgB1vYwyZ2sY3ttoAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship among urea clearance, blood flow rate (QB), and dialysate flow rate (QD) during sustained low efficiency dialysis (SLED). The flattening of the urea clearance curves describe the conditions in which increases in QB do not enhance clearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kudoh, Y, Imura, O. Jpn Circ J 1988; 52:1171.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20814=[""].join("\n");
var outline_f20_20_20814=null;
var title_f20_20_20815="Pancreatic duct stone pancreatoscopy";
var content_f20_20_20815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic duct stone seen on pancreatoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 368px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFwAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKUDPSporWeU4jidvoKAIKK2Lfw7qM/wB2Bh9eK0YfBl8xPmsiAc9aV0By1FejaP8AD2K7Yia7ZSBkbV6109v8MtICN5s07EAY4xye1Cd9geh4lRXvqfDLQAQ2yd0UfPzjBpk/ww0dY/ljmVxz97PFVYVzwWivdT8LdKK7WadHznHXA9aq3HwksGDGC+kU5+UMnUUnoLmR4pRXrd58IJ03/Z7xHwcDIxmue1D4Y69a7ikAlVepU5pXHdHC0VqX+g6lYOVubSVCPVTWayMpwykH3FMY2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigByjJp+zA5psZwaV27UCGMaSiigYUUUUAFFFFABRRRQAUUUoGaAEpQCelWbe1eU8Cte00yPI3/MT2pNpDsY0NpNM2I0JrbsfDUsvM7hB1x61t2FuiAbFGRyMd/rWnAFABwFBIyAMkCpcuw0inY+H7KFCxi8ztubjFbkNtFGSsSKuTt2qOMfWmxDJUk5B5BboatQ4dcod4z846Bazu7jsO27gcgk52jPTHpVu1tFk5IRWzyw54qFVA5IUqeBz+taenYSQBnAX7rHb0FJpyC9jT02Ew5V8qG+YsF7e1bUCMcCQSEYLNz+Rqhao22NY1aTLYVy3JHpitGAKy7MMCecLyQPStIQ5DGc7k6xlRlkLuCC/z4yKlWPHzCMOAdrMW4AqNMMpIVJCwGcfwf41aRQ4lIUS7cHzB8u38O9aPuRcYqlU3jKx5wz5zx6CnpkGMbnJYYGVB49aeMkCfOVLD94B1/4DSoMbdgI6/MDhj7Y7UJdxEUYQ7SpQgjYcr096VI9wULGpyDxuxnFSgYGxeCwyAvP50rlWdgZA5I3MNmOe4+lKw0VZbeK4BWYKQy4ZpEBGfasHVPBOhapGHm08RgjG+M4JP0rqAh+YKdwT5/lOVT8O9A+ZWlGGw4/eg4I/4DQVc8c1n4OgjdpV4GYgkow6fjmvPNc8G6xo/Nzavs/vDkV9SnbwpCvtO0IV2ls+tRSxrInlyYY4KsJACAKE7jTPj1lZDhgQfem19K+Jvh7ourp5gh+xOU+Rk5BPuK8k8UfDfWNGYtHEbiHGQyc0XKujhaKfLE8TlZFKsOxplMYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKDiikooAKKKKACiiigAooooAKUDNKqknircFsW68UXAgjhZzwDV63swOXBNWoolQfd5qdEweRUcxSQsKBelX4iAPmHGM4NVkX14q3EAQO2RgVL1KuXbccLyCOm3pWlb5G08o33Sw54rOtwOBuAHcsM81pRDcMhVzjoDiklYTZbtl24C568+pq6i5KjaHJ42jjFU4xjAJ3qOSTwauRLlguwsQT8ucGm4gSJn+EgsBhgR0+lXLdtpznI3DDHtUEQyMEb+OnTbUydPvbm4OSKErEy1RuW06EguwbL4yOGrUgkBwAWKnIAU4b8a5VJWQMA21g3cfN+dXEvWUBCPmBzuz8351ukmczujqIm34DfMVUjC/Lg1Z3CTJdvMkVQVZeAPrXN2175m0NGWAyCA2N31rUs5jKioPnIX7g+Xb+Pei1hKVzVVsyO6EMwYHzB8uPwNSO2S2VDsX5J+Vn+lVN3mjJKuQgOWGNv09amdgS28ks2D8/wB4/j2pMaZKQEJTaUIfiHtj609eQiKzMQD+7/u/j3qH7jmNvly2RHnI/OnqxbZGSpAJGzoF/wCBUwbFjXfwvz4Qkj7mP8aHIbe20O4AIP3Sv09aTKsI1dsuARtPT86aXzgMNwK4BfgD6etFykOclQ6liA2Plbnd+PakPyEoTtZW+WMjcB9TSD7rKG2KVG7f/F9KQ7VDfK6KQMLnP61LGKDsyVwpIIJPIP0pDGPLZSBhl5H3g3+FOUYYYYLhsluqr+FOVBjOzOXwz5wrD6UtwOJ8YfD7TNc8wpEtpeY+Qx8g/WvD/FXg7VPDtw63ULNCCQJVGVNfVIjyVCoApPEfQY+tVryygvbcwXMKTwMGJhx92lctM+OqK9f8dfC5ow15oREoI3NCP4a8knhkgkMcqlXHBBqhp3I6KKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFOVdxpUUseKv28AAyetK4CW1vjlhn2q6o2/T1NCjsPzp6DPUZ9ql+Q0PUDuR+VSxjn7vfHWmDPv8AlUyDJyCM49KmxZKiEYJ6+9W0UEdBz+lVoxnG0frVqM8Dnp+tCYFqIZxtRgD0Ge9aEBDdCNxXncKz48ckjvkc1pWx+UbgeOoIyBQ2ItqcKc5AK5G4ZzV2HJOCPmz0zzVJQMEDjjnP8VXIRjA29ccE81VxFuL5hGn3uoC9MVbTJUbXBypLZGMVWhGGVWXcu4jb2/OriZCoCcKMgKRnFJiuI64DfwqQCA3OaY6bWI2beM7amG0x7hlVAwSecU1vl68AjgA5zRqgFi6j1z9ytqxkBWOJjuIJwjdvxrJiUY/2s521dhBB2DHBB29vzqoyfUiUEzct5dxRc5bkDd0X6GrIciJ+diOuMtzkj0rJhdlEeT8gYg7hlatxSZVG+6gJG48j8qu5lyls/KHGDH0Ozrv/AB7VLu5IIAy33B92qyt8qMAyBhy2c7v8KcsoDr86ouPuYz+dDFYnVsMAMDk8NytKnAQ/eODw/T8KiXP7s8LnJwxyp/CnoCUGMBipJ3jj8Kll7Dx8o7BtuAD8wp5jIZswuoVQCd+eaUY+fYRtAG4BcA0LGvzHbtyw+fdkYosFx6j5hyGYYKsn3V+tPA2lXOAAxy+dy5/3aFy+QoLBxuZR8ox7UiHCLtwm1eqDJ57GmJikYRcgoGU/N94N+HakK7mBTLvgfvF+XaO/1pSfLcshaN9uFAO4N/hSSghGyh2qNuWb7p/rSsCImPGCcBuBjuvvXB+PvANr4hjknsgseoDn5RhTXfbirNsfJPyDamA/+FNk4O1xuRTtEbHlPfIoZS0PkLV9MudKvHt7uMo6nHI61Rr6e8deD7XxHZOp2pfRj92yL94+5r5y1zSLrRr+S0vYykiHH1plpmdRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKcq5PFJV2zhzyRQwJLaDau4jmra+xOfpSKAO3FPxjtWadwsA4NPQcZ5xTKlTIAHamtBkijJxtP51ZVT2qBAAB61YUY64H40XKHrjjnP4VPH97tiogPmyCc1KnuB+VTa2oXLcMhDjoQOma0IDlRxuAOD83WsyIfNzyD1xWjatvYA7TxjkYpLUC/AMH5iVAGMkZq5HhYzuypwPl67/APCqdu2NpyAp/GrsAYkgA8j5sHOadx2LcQPz4UAK2SQcgfhV2IgMCDt+YDf1qnF8+TsQgKOQcY/xq3G3D4O4kA5YY/KmZsmUMBkcEMQX7n8KYyYAKr1GD71NwWJJyS2QTw1Mdfm4HGccfeq5LQSI7cktgHP+z6VrwAMhHsCQOgrETJICgH2B61fspW6EBsD1xt/xqUhy2NeNcnKt8ob7x6VKg+bfnGG+9/8AWpsR3ruJ3AAEE8bfp61ZVF80Opbbn75HP5VexmhI0+dSA2dxyynBP4VJES20Z4APRcn8afGigguAyhjkZw9TqhAxlvkByg+Ur/jQSRKAACQqnack/Nu/wqfaVG18I2zI3nOfpSLhd2GCHbgBF+99fSpQuPMUbUc4XYfmLfSgG7g5MqMXUucD5s7dv+NKxbzSQVYj5VKrhTSup8xXaQhVXC7lzz9KbtzgeWTxuYM2FYfSncQuQSysvI+Ugtkg+tSlmYBjt8sAKrDgN9arqygLycKuQFXG00obaw37UfGRn5t/+FICYMxGASwJJeNeAQPQ035QFb5EDncpJ3YFMblAOe2CeNvrxTlbLMI9okf5doThhQAuG4V1kZGG4jOMmmEgAgNsfGFAGd3405x8uTgAnb8zZK00ZYlV+dc5KgbQw9jQPcY6bNytGUVP4N3IP1rkfHfhS18Sac4ChLyIZSQLy59664DAyoUFTnI5I+tNbdtyykqvJGcYNSxnyNq2nXGl30trdIUkQ4INUq+gvif4Pj1ixa8to1S7iXc2DkvXgE0TwytHICrKcEGmjRMZRRRTGFFFFABRRRQAUUUUAFFFFABRRT0UseKAH28Zd61I1KjAFRW0W3HHNTnAHSobuOw4EUo+tNB96eAcdKnlXQaDJ9akXntTBk09eKWo9CeM4Py8Cpk29uPwquD3HWpVPGCePpVJdwbLCZIwBUqn1qFPm65NSgH060bgi1Hgk9D+FXoT+7GSRzjaRms+EkZ69cVchJLdDg8HmiKA07dggyGUEfLnGeKvwEKc5JUcZXgms63boHc9OeKvRE5JOS2csfT6VLiDZejPmNGCQ56BcY21di/iDHc+3Hz/ANKpRZwU52DkIRkkfWrqHHy4+XOdp6Y+tNEssgEFtx/hH3uTn2pGw2MqSpP3f4vzpIiDt+dipOcYzz7UpJZCp2u7Nk9itbdBIgUZKg854x0q/aBTgFQ5Udzjb/jVNR/DggZ6f/Xq/aAfJkhjyNpGAPxqE9Qlsa0QD4IzJhMhmG3bj+dWxj5pC/zEjLsMEfSs+2c/uwSWwCPm+6v0PerqSERklsKV/jGc/wC76Ve5inYsg7i+G3gt/dw9PwCqFxtBORKxycfSmBwSpLO+xAQcY2n+tOAAYKE2NjHByHP9KAZKuT97kOwyAMBhT42GFRSdobcyoPmX8aiHyb1YDIG3DHJX3FT8uR+83hfkRwNv50CFO4BXPytJna/BLn6dqjddrENHjA5DNk59RUgCsSI1UZ4Eff6g012C/P8Acjz0HzNn60gIpM7eWLZ4U9AajEgDuBtQEhWUDdTnGPvgKduck5DVEr5UfMSirxgY2mgqxOpxh+QCcKx5JPuKcWKgISSq/wAJOOfY1AmFOSFVgvOTncf8akVsIAshKjq2zJDehoQh5YAqAV3A4yBndQwPKnftjOQpHQe9KCfuu74Y5kXb3pACQd8b4Bw2X5ahjsMbaASqAqDknO3cKjbapOQAem7724+lSMG3AyEgj5GJXIFQtjAwOv3QDjn1qRpETldm1mUAHP3M5PofavFfi34V+zXB1OyQmNz+9AXAVq9qbccY8xsnnnvVDV7KPUbOa0uY90cg2sGYHn1p6JFHylRWx4p0iTRtYntZBwG+UjoRWPTKCiiigAooooAKKKKACiiigBRV6yi43EfSqcSlmwBmtmBAqAc/lSYDsADjr9KNvqacPpRn3pWHcQClA9/0pQMdacBUtWGAWnAUKCetPAPqaYAnNTqP85qMDFSezYx9KNWIfGD1xz9alXHHA/OoBjPAH5VOvHG4YPtU6plFlD6Y6VZiYZ5AP41UQ5PGeevFWFbkYYenTtVK1wNW2K9SM/XvV6MDAIAIXrz96sy2cgrjJPTp2rSjc4UnnAyBipaswNG3JAwBhh8xbd29KspnkKu0EAhQc8VRhxtGdpx0yv3hVlNvYKQDnI4z7VS8yWX43I3EBy33tw4xT9wKlSflzuHy8mqygKfnXOByN1WFyrY+YY984FW9hCS5G5ep67RyB+NSwSFWwBk9QlQltwXazdMFQMZFLG3QYLKo/KoUbA9TVhnOxQxyFb5eOB+FW7ecnBAO0thmznNZUByoIYnjp6VOmVbccZXkHPFaJ9zJxNwMSoZj8rMMOxztH0qeMhiPlDAnrnar/hWPDNt+6wGB1xVyGTaSGjXhTuVmzk+1OxJoxMgCAOVA+bhM7T6e9TAH+NVzt3MWPD//AF6pxyE7FLbzt4wcbR6VIs0e0sAFQn7hHzfgaAJ2IKZGZFVcZI2+Wf61G52nKNyOFdR1NNkbnLZ3g5L5BwPpUMku4k7CR1IJxupMaQ6VsZ+XYvRxncT9Ki3EspYkA8hm7iog/HBxgdh0p2CrDgK23JLHdupDLELKdvzlQTkhU6VMm7HzbmUncQCBk+tVY2YA7S2QMYzipAdzLiNQ7cbd3SqWgmThsqhKHcxwctgmg4BDtlWPDO3zAtUYf5Sx6nhywzk0NkLhFI/iUKcj61NuoXAEOAFTcSPlCtjaf8ajZgVbfJjIzllzuprsGYtvDgDcSRt5pu7buIDJk8dwKllDJU3IwaM9dwVX7VWkCbc7VVXPc8ipnK7slAeNvDY/GoHyB8zAE8biOhqZGiPPfitoY1DTRexqPPh4Kqvb3rxIggkHrX1Fdqs9vJHITskG1yVr548X6WdK1maIKQmcrkU4vQDDoooqwCiiigAooooAKKKcoyaALthFubce1aeMDo351FYx4iGBU7L196XUdiMgDoKMc08ik79RUydnoFhM0qnpikx7Uqj5h2+lO4x46YxzUowcYHWo1HNPGAvP/wCqpigHAZqQdOOKiB96cvXpVASr17/nUijkZFQoduMc/WpF+lStWNllMg9+evNToRxwfzqpH7gVZjI9MVOzGXrbLOMZbj+9WnBltvHB5+9WREQWGAMkY9KvwfNuIVSSOh4x9KvcRsW0hKrktgfwe1XQ/wAvUDGMYHT61kRPjJJLADk+lX435B4xwM9qGyWXhhGU/J8o69jUkeBjHXPO09arJITITwfm6fw1LGxZhx3yQOB+BppATgZ4OWHOxc4K05VDAc7sD6bf8ajTkYByBnIIxU0RyoJywUAZxjb/AI1SEW48YOTvUDr0qXOAeQBnAOOKgU7tz8Pk4DdBTi+Rwed3T+H86bRJIWJPdmLc46VYt5QoCAgEnIOMnNUdx3hQRgn7vb86sW+WwFJKnkcd6afQUoo01uAUKuwCnkgJ3qVbgswLTEArtY7Pu1nKDwMMcnnPrUisRu6kfxDd1oejJsrFtHBH3VYEdAcfnTSWkUt1HQsx6fhUaZYncG45bHanj5m3k8tzvx9z8KTBEhJyc5dc887aBzkKACeNp6D8aMZKkbHIbGTxmmjqqnk56H7tICQkYY9Bx97kmnEhVIOBg5EZ5z+NR8gAZ28kEnpT1yBkfuwV6dd1FwJA+1twyoVsjnIUf1pcgs5/izkkHbvHp9KjIIA3Bc42kdqTJIyXByNpLLxRe4DmLbk3HleBkZAqPGQAvY43KetPHCowUqCOMHO6mttLEnBYjOR8uKQyKU8ncQCRg5XpVd8bQdnysNq/N39as8n5kz8x3Ase/vVWXqSTtLjk46/SoZaIG3E4IOTxuLV5v8WtK+0Wcd+ikuh2s2etejMN/KoDgcYPSszxBZpf6TdREhtyE5Ixz7UloNnzfRU13EYbmSNuqsRUNagFFFFABRRRQAVJAu5wKjq5p0ZaYcZoA2YV2oMAninn6UqqAvX8qXbjqOoyalblsjxTdvPQVIVx6+tJjmlJaiIsY6mnjGaMAe1AyOQOaSAcOKMnJ5yD1pvNLTi9QHKT605TUYBp6im2BLH0OQaeM1Ere1SlwegFTsBKhqaEnGNxIPXNVFqVDjFT1GmX0OcZ/M81chkUgFuuMHNZ0ZKjk49qsQvgnGMCqQzcjwzZJLdACeMfhV2NsLuI4JGG/wDrVlW8hbDe4+Y8n8q0YmIKseufvn/CixJcjwSASNuc5I+X8qsRv8qjOV54PANU43wA2Bnnk9KmRvmAGG4/j6CncC2rb9ufmwOM8Y+nrVgMWDENzkAkjG38O9U1yQMfNgc7v6VYR8knJOCMMe34U72Ey0u4Dfj+L7//ANang7jnGfmzn+H8qjVxgMe7ff8A/rVIpAILH73Oexq3sQtQQbTkkAA8gjir0GSVAHfd14FU9udvBXjp61LGyjgsDg+lTFhItoMrl1wSOc8/8CpcDptXg4HX5qRGBHHpwc8Y9KepwOBg9uegqpdyV2HAhW4Xthvm61YUnkHJ7swPUVWJI4Od3UDb29akRlUjkFQOCRjdSROqJzk5ywyWwdy9BSAgkEHJB+6en50BuD8nGOWBzSksVJBBTP3scflTC4iELtP3Tk5Y8ipF+WNWI2qwxnrv/wAKjjYpgrx8x+bqv5VLGQNh5Xdn5+ufw7UAhzAjdn5BwcDkfjRJkTclc5zkfc/KkUgDp8uMAr/WkJwCScHdyRyPyoZQg4BP3STncD1/wpjEqMEsgHzBSM5peR833c5yf71MI28nIO3jBzUsBrgN82AQW+/6VWcsCMBs5J9gKmdsKSeuRyORVdmzgrwc43Dr+VS0UmNcDg5yoPpjNQzfKCWHAJBzyMVKxO0HlRjA5zzULZOAoBYgkKpxtrN3KPAfHlmLPxFchfus24cYrna9G+L1sBewXIYsXXnjGK85raOwBRRRTAKKKKACtPS1+YnGazR1rY0pRg5x6UmBpqMKCpAPtSHPPA9Kf2BOB70cDp1PJFRexoRk8cjtigqRTx7YFNPX5cH8KnmdwYxselJj604jmm4weBWi1JDik/KnYPfikwKl6MErgOKetNAJoUGnYESLinAD1pi4PYU8YHana4D8+lOU49/pTBz0/Snr154+lS4jRYVs+1WI3AUAj6iqanFTRvzg4x6UrDRqW0mCCeCDnP8AFWpBIDsOecdRzWFbuAw7D1rVtJQq5Bxx25xTuDRpxcBcnGV4J5zVhR17EDo3NU4iEPJ6j65/wq3Hy23HzE/c9fxp6Ess7gMgg4yABnk09X+diAfvYz/9aol5yoGMn7v8Q/GnbfnU4BbOc55p3EXY24U42tn73X9KlDEADGCRyfWqaMQwwFJ5bcDjipE52fLjvkHoKExWLG7C8Hceu8nn8KlUlGI5G0Z65qurZCEtznpt7U4bE4zkA9QcEinsIuxykrjeeDuTIzmpllXaQSrDrkjGR6VQUlccEY9+gqcSnjHbkAjPFXdPYmzLgf5s88dTnt6VMjMgAGcrx82CAtZwkA43Bgp446ipVcYOGx36df8A61Jg9S+Hyu4DeucIy8Y/Cn5GSxJzn73/ANaqgYEkjDHrvzj8hUoJ+YryM8k8NSJsT5wd/wDDu+//APWqSMkfMp9Ru7n8Krg/OCB85br/ABUqyZfg7nz/AMCoE0WVbI+XDbV5KcYqPfksV+YgcMvGz/GolbfkckqOQOMf4012ycZG7bkKeAtNhqSPKACUkG8Hkkfe+tRt8pb5TgL/AAGo2kyOWIDDO5hnP0qJmDFtqckcBTipkyoj5TgMy84xkjjFVmc7iTyA33v4qWR92TnceMMeMVCzZ3dyRkMeM1Ny7IkV1Rxzt+br1P5U04OAQDycL0P41G7ldw3YJOQpHJ/Go3fDbSOQfu//AF6mQ0jhfivB5mkQybyWRumP615HXtPxCIbw9OjMV2tkR4z+teLVcdgCiiiqAKKKKAFHWtrSziPOcc9cVir1rb037gI9euaTY0aK8Hpyepp3AGDx70igZ6Z5xilAJ46/XtUp3LaFPuf0pGB78560vJXofrmkIzim0IZjnnimlRu7/lUnbnikbk85/OlEViMjHoaQjFSBR3pGApNa6gMI9sfWnCj6Z/GgcdKdxoUU4HNNHHalHBppXAkB9eacp71Hu5qQdKTVgHbh1xxUqYzUQwB1H0pymgZbjcZHtV2CXp/AAMcd6zFb0NTxybTw2KVho3YpMBgTjceUHOa0rdwDtAx22dx+NYFvJgbVPfpWlaTBiq4B5+5/9ekJo2U5Uofug5Kd/wA6MsxX5QWHI56iq0UnAyyhcZwR1qX5Wxjacjd+HoKqOm5BYUgjrgk7hgdfb6VIpB6FWU8tjtVZSynIG053DnoKsJkEYbjqPl6iqAsqSM4yAOM57VKuePUD0/h9aqqRuHO4ehGN1TIQFIA6HBO7qPancnck429QQDxx1FHAOBzz2P6U0kgc7sjg+wpC2SMnke1L0GTq77vnbGODgdqkWUhfvnI4xt7VVzyB1A6n1pwkI4PIHU5p3FYuCTG4FgcDAVh1qbeQTx8wxkE5qh5vzMCfm287uefaneZgYHGccZpcwuU0DIctk4wfun7350u8j5W656d6zxMPZuehpVuM8EDGfuk8fnRcOU0PMyuARjHA9KCwdWVu4zh+uKz2lJBzjp1PelM4AO3qV/j5IpvUmxcdzjKjG09zzUTP95hggH8aqtMcYYEnPTvUXmkuO7Z49am5aROz7goLbuOQ1NWTAz228lufyqIMWwTkDnk803dtxjg45NJ6jHu20FScEjODyW/wqGR9qspO0Zzs6/rSs4VWy21SOcc5qtNJhWw2BgHHWploVE5v4hXO3w/OgYgFgNvX9a8er034lSMdNA4Cl+i8ivMq0jsJ7hRRRTEFFFFACr1ra0w5iPsaxK09LfkjHWk1ca3NsEbfXBzmnD0xz+ppq5wwzzjNPxgfN09KxtroagQMjqT6GjHTdxS8YHp6UnQZAOB3rRCYE8dc/Wmkdexp/bOOPWgDKgr3496VuwmhmOc0hGccU7/e4pdvHIA/Gkm+orEWMDpQAO3H1qQgY6frTD0PtVWTAM96O/Q0e/ejA7CgBRgc0qn3pO1ABHpTAkGD6U9TUYB9qUHFJWb1AlB9s1JH15FQKxHSpVJB7UXsUi7GTgYOF9Ku27/IADlvSspWOenHpVmJ+QcAn60XBnQW07ELhz8o4yKvQyk7QWzjkfL1rnreZuOMHt81aMExbknPpz0qZMSRqFkwSCDtOeR19qnhkPAYZHU4boPSqCTfu8ljgHFSRyKThTlemcbc1aJZrR525YsMHvzgU7bk8jJHGMdqq28is3TcWHQNircLFk3fNjo5J7UEBgem7HXnrTghHoOxOeo9qcrHGckJ91jjoKQY4B2kHgZ7CqdlsAEYB3Egj5SMdBTQnIOFJBxg8ZqRRknIOOmQ3Wg5IBYnngkjNLQaGEbVwCcE9PU00sfukgZOCCOn40kpBwBjJGfoajzgg4IAH3T3qCh7NkcDAz+FMSXkY6f3T0/OkcdyAdp6A1Fkg4JJweVI/rTSAto+5QfUd+gpxOc4PGO9QIcDkgDH8RyDTi4XaCcEjgHvTRJJk4x91s/dPWkIIxkYIPbrUUj4LAjnPSmrL82OjbsbP/r0twJg2cFR83PTrUTPzjJBx/DzTTLyBwRz8o61CXOMZ6LkbeDRYpEjswBwR0xx0FQOxJOSOo+lI7deBgYJxyKjBDN04z93+H86zbLscp8QwDpGTwfM6AcV5lXpPxDlI0xItxHzZKelebVrHYyYUUUVQBRRRQAVd019soFUqmtn2Sg0mCOniPyqRwMYzUoB6jp7VXt2BRT7/eqwvJ6ce1Z2sbAAD0pQMk4znrmhcnvk+lObHrkYp3AaDxnv60rDuT1PFKePXFIc4HBNWkJjcfj9aT8ifpTwCT0oxjGO/SpauFhmMdP5UhBOSOT2p/zZHH0oK9Nq4z70bAM5568U0jPTipCOeg49+tIFAxSYWGHilBB5pxWkK9hn86L3ExR9aX8aBn16dKd7YGKFEEIOO9SL0pq575pw6Ubj2HjpUqt/nFQjpThnNFrgmWo2GACcDtxV63nCjAx+VZqMOM5P41PFIQcZPPXik4gzbjclgy4BHQg8VOjncvPPUhulZEMuAOQTVqKYdMAYHc9apMk1oGyV4yOeDx+VX1lGQeXAXqeNv+NYsc2OGXgjjd/SrQnDAAEuQMAk4IochNG0rhhjcW5yTn71SCTkgv1OW+XpWOs5w53BuNoBGMVPHcYIyABnB5o5khcpf8wEnpyccjGBSO5BZgOQeGDdarmcEcscnrnmmNKrYZiMngqRwtDa6AkPmlzlGPQ524603zDhT82M4yDn8qrliR8pODx170Z3ZIwx65BxilcosFlI5OO3SmA84BYZGdoOc0gYKHxuAB6ntTN47BWwccHBNNCZKHBBwQ2R3GMUMSoPG0EdDzmomY52kcE8I3enqTghTgk4zngUN2FYc3BOcqRjC+tGf4DgndnYP8ajz97aCMkADrupAd21ehB5T/69A7Dx8zAYLAk/L3phOQqj5g3G0daYSflUjOM8A0hbhe4C5wvalcpWYjYI4PYD5eB+NNboV6kHJTt+dMyBjBGfQdDRJgJkk4GQCei/hWY2cB8RLotcwwCQMijoO1cZWz4suvtWtTvwQDgYrGrdKyMgooopgFFFFABSrwaSlHWgDodNfdEPX1rQUZHqfSsTSZBytbSg46YJ7hqh3uaJ6Egxx3Hp0pOccn/61OGO3680mD9f61L0Gg2kLznNHQEgDj3pT07Uh49Md+KV2xiDHrRgZPTn36U7jpk4PXijk8jv14p2aAMcnpSdzwPbinbc9Qc0mDgccn3pJPqAhGdvT8qOKXB7Dr0pQM+v1zVJAN2+gH4ikxz/APWp4wen86CpA7/nTdhWG8UYp2D6ClKnow4H3qFcLCBQBjtR+FLQR+FTcLAcinKMfexSKDzx16U5c9+PpVCSHJ9alXnkDB+tRpkdz+VLk5zjn6Um2h2LSsOe3pTllK7gAAMdx0qsDjv+dOQ4xQFjQjuAMjqMYyeoq0lyDnLbhxz0rJ3gdyMdeKkVzxk59ah3uFjcjmySHA65561ZSXGfmwMbSdvSsOObAwMZ9auRTqQCSVHUAHOTVprqD0NBZA3TGc4xmpA7HIww7detUt+dxJHzHk46fShJsnAxkjucYNJNIRdZu/J3cFh2PpQp6Dau5uCKqhy4AAPPQBu/rSs42kEkKRVNXEWw2QCAyqwxwc5NOB3HDEFiOcjGDVZSdzbR833shsYp5lAByTt+8ARnJpXHYnfPYMoZec/NupkkgyAdpyOnvURkOMghgOeDj8qjlcICFygzuxjNF0wsWGk3cdFHON3SkL8EBiI85Ckbv1qk8q4zuBGeMjGRQJvLLcc9MK3AFLmAuNIMMWkBHpimPIN2A/OOuOPxqu0hXoCAOTz/AA/41G04XjLA559qNwSsWdwwcA4BwQvAFUNWu/stjK5KB1B5J6mp/OyAWycdQTjI9a5HxzfBII7VGVs/MSOtTbUG9Di53MkzuepOajoorczCiiigAooooAKKKKALNnL5coOa6W3YMoPFckpwa3tKuNybSeR0qZK40a4xjGBn60vTGOp/SmqePvDHUfL1NP4zjd177alXRdw254J/CgZw2c+/NLkZ7Y/u0nGAe/8AOhsoXHv1680zB3DOSD05pxBwTx+VJ6c/L/KqTbAMcj/Gl49Bz146UEcEkj34oPPJPJ68VLjcBcDngCg4zkflinBGI4HvUixu2MZ596Ix1BlcjGMYP0FOwADytSOjLjtmmN3/AMKpxVwTGZHt+VA4OM4o59+BkUc9jkDpSGJkelOHpnP1pMnFKrc9TycHik1YkkX8P8KUAE4wKQH369afk44I/KhysCHDr0OM460c+/PWkB4HHWkZs9KLprUVx2c9SfyoHHfpTPTg/nS5J6/jS0ZQ4FTjAz6808Ow/HrUO7PfNKDQ7bATiT3Iz14qzb3BOAp/AcEVQxluc/nT42G739aSRO5rxynkhCCTwc9KsA9ixIPILDJzWVA43AkHB4JzV6KTHY4BxkHoKq4WLWVwQCpx82RSj5RwCvfHXFQiQr0JGODkUBgoyVyOmAcUbBYlVwuCQpVfXgtT3lCkDuOSwOcVUlk+7uOGPVjziq0kg2ruweMcHGaVy0i79pKkcg4bG0r2ppuDwwIypxxxuFZzSs2c7gSME1GZM4BYFiOnpU2HZGg05yeTuHGCMgCo3mGF6A9DxVMSHhckKRggHrQzEqM7sdCapxuKxI1zgjOD2pv2jGDzkfe561WkJY9T6dO9RMSAMn9KlXTHbQ0PtYSNi8nAG7P9K4DWrs3uoSyk5GeK29evTFb+Wrnc3BFctWsY9TGTuJRRRVEhRRRQAUUUUAFFFFABVmzmMUgIqtSg4NAHXWshkQFcn056VaUNz1I7YNc7pV3tbY3Q9810EbBlB4APvUPQtakhBBAGAPU9aT6nP0FOBzjH6UhyfX25o5SkxBnPQ4HXmkx2wPXGaXPOOMGkOAc4Xpipu0MAp7g8deaUcdc/nSY6Y/h7+tLj0IH4Ursdh6AAcAcn1qwjIqn7oz1B/hqrnBOcAHqcdKcHOBnJ7H1NTFtCaHyMMnGG7CoGIb3HuacSScAAnrikPUdAD0qmrgrIZjr9fypuBnripMdu386Qgg9+evNO1wuNwMdqXgZ+XGB/eo5PXPvR3I4P4UWAdux1xTw2flPP0qPI4xgUu4ntilcB+7oe3elyKjOM9P1pwz/EB+dN67CQHpyKPXj9aDzx69aYTjhsD8KErag2SKT05wetLjPRjg9TTQQeu2nFgOp/AUpK7uK4uRim56cDNISRxmkPr3PWm0NEiktjdkjHSrgmyAQAMjkZrPD5GR0p+/JO3oaLDNQSsVzggHj73ej7Qe7Hkc55rN8zIIB+nFNLkfdNSrtlF6WXn5cDPpTTJznuegqr5h557ZoDHI5yPWny3Y0TM2fTpmmsew+UHoKYGIPGeOmaVccHAP40n7rHy3Hk9e3GRmnM3Jz0A6ZpoYqcE45xz2phcjG0KT3yKTfYfKxX464PHrVed/LjLN0XrzTmcA5Jx+FYOt3g5jjPH86cUyJtJGZqNw1xOSSSBVSlpK3OcKKKKACiiigAooooAKKKKACiiigByMVYEGuh0q88xQrNz0/CucqWCZoZAynFJq40ztUbOcAkZwCTTztx6c4+lZ1hdJNFlQMgdCavo3HB49QKk0uOAPG3v8o47UN9R/hTwMcEEgDjmm/Q98cUnFvYLjO3QnHX0pFK4PcdeKkCgZA6Himnqfrj2pPRFXEPpjn0FIT6ev404gn29qQjIJHAz360kribDIzg4PP3cUZHGOP6UhHXk9fu0Y796pC3E9zg846Uhxz0OKcc5+Y4GKQg4J4B/lUtXYxpHHP/AOuggge9Kep9elNPIyB7U1cAzwOKU4xgmkPA/rTScjqaLdwHA45JH5UZ9hTA3y8YpMn0q1YB5YA0mTjjrUZJ7nFL39qQiYfXr1FLntk89T6VCWwMfrS7vr7+9AmSjOTlelJIx5x0FR7umDj1pm7pz+FFwJN2P8KcD681XLDNLuPrS5bhcsBj78cigsCeQDUO4Y/DHWkyD60ItMuxLld2CBnrUpA4zg446VXif5sHg461NuOMk9aTLihjEA8jvimb/XBH0pkjZJ57UxuRxWduY2SsSrJn8qRpDjk/pVcsOMHGfSq97erbxkg4Y9s0JX0JnJRQmqXohQhSNzdMdq5p3LsSx5p08rTSFmPWo63irI4pO4UUUVQgooooAKKKKACiiigAooooAKKKKACiiigCxaXLW8gZenpXTafdrOikHce4zXI1NbzvA4ZD+FJq40zuY3A5XHHTinZ685wKydOvkuBjID+laaODn3rNs0ViTHIwcgcA+9JtGcn1/CnL2yOvPHSlBGF4xxn2okNDQhJAIzxnmmMu7k89+e9TEAAZ4IHekPyg8HkdDQmDVyLYRkNx/s0hUgKccZqYgDcMYAGdpPNIy8nC4HUY6Uc2thWsQ4+T0X1pADjgH/Gpgvze/r60hXkjbhh2FMCHGAfrUeMn1GfpVsqN2MZPTmo2UgZPToM800BXYYb09qTGeT+dTbCQ3r2xTGXk4+961LZRH35GRSEAE+1SgE9veg4wOufpTSJIB7HFIcVKynoOg6Uwjmm0FxjDHXpSFiKdgnpx7U3Yx6ilYVxM+1Ju9qds+tJt654xQ9ASuNBz2oz225FGw+tLjnoaV7D5RDgClBGOtAB7mjbx1p7jWhIkmOnFS+Zwc9O3NV1Xt6dKcFIHPTpms2jaMh7ud3Xv+VM7c4FISARn71Ub29SDKghnqVFtlyqJIkvLsQIeRnsKwLiZp5CzmkmlaVssajrojGxyTm5BRRRVGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAD45GjbKEg1uafq5O1JjjHQjisCik1cadjvoZgw+VhtI6jnFSqf7oAboBXF2GoyWzAE5X3rorLUop8AYBznbmsmmjRNM1ARz2xxz3p4GB2AI5z1/CoI5MlVPPP3c8fnUinOQpAY/pSKQ7aApU4K56Ec0FM4VuMnoOtKSMHnkngnvTujEYIOenp+NVZbiuIy8ZBDE8dOlIy9ucMcgetSY6ZxjPUUD7rLwWxn/d+lF7AREAHB655X0/GkK4ycHg9uR+FSsMZ4wCMgdaRgDwMHIyQOKdx2INgOAMbs4wKb5e7PGSfWp2AyB2znB6mmsPmwRge1TcZCU5yCeRjrSCP0H61NgbcZGCcHjpQffA7cDtQm2xWK8kYz0Ax2zTdgx1Gc46VZbAXAJBXp8vJpHHzYXpjOKqWg0iuV+XqAc4ppA5yO+OKsFceh49aay8qMkgDnHGKm9x2IGTOAaMfLgAEmpcfMoJOen4UwKDjgn8aew7EW0YyBSKuBzUrLn3x2ppTk4OR0yKSYWI9uTzQVA6/SpNp2gY5JwFo7gA4IOTTeotERlRkYI5prsqDLEEY9OKgu9RhhU/PufPSsK7v5J+Pur6CiMe5MqiWxcvtRCgpD17nNZDMWYljkmkpK0SsYtthRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTlYqcqSKbRQBqWOrSwYWX509DW9aalDOAA6gn+E1xtKrFTkEg1LiilJo9BSVdq9ACv1/KpRg9cgYHA5zXEWmqXEB+8WGMc1rW2ux4w6lTj+E0muw+Y6PIySAMjncKdnGAT0P3T/Ws+3v7eYEpKpwMAE4q2kvqcAjBPWixSZL0z0ypxuB60EAY7rnpSZVjyFPGacpY4AySwxjPepbV7FIaPlbb0759KANwBHf04pTnIbnGMdOtBOCCScDtik4hcZjpjKhh60HJwecng89qDjkHHH6UpAPIAAPTmnflVxrUb82M9jwOecVG2AAeMZ4OaU7R+Pv0pMjcSFAz2xWbbkUtBqnOeh3e3SmnJPz85P50rY5HJ/Gmjbnjof0rS2hWgDPLD5R0BpOB/DzSOwyCRlic5JxVaW/gjGJJBtHQChakuSRYzwM8DsaaTxnrznngVkXGtoMeWu5/XNZNxqE855cgegoUWS6iOgudRgiwCwf2HY1i3mqSzfKh2r7VnEknk0lWo2MnNsUksck5NJRRVEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAChiOhNWoNQuIfuyN+JqpRQBtRa/cKMOA2epq4viNeS8PPqD0rmaKlwT1HzNHWL4ggJ+6y45Az3qyms2xB/esO/wCNcVRTsPmZ251e04HncdTx3oOr2xABl9+neuIpc0WQczOyOsW3OJPvdeKry67AGBwWI6VylFPpYOdnQvry4+WIZqpLrU7Y2YFZNFSopA5NlmW9nk+9IcVXLEnkk0lFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatoscopy showing a stone in the main pancreatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_20_20815=[""].join("\n");
var outline_f20_20_20815=null;
